<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1d3 20150301//EN" "http://jats.nlm.nih.gov/publishing/1.1d3/JATS-journalpublishing1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.1d3" xml:lang="en">
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">PLoS Comput Biol</journal-id>
<journal-id journal-id-type="publisher-id">plos</journal-id>
<journal-id journal-id-type="pmc">ploscomp</journal-id>
<journal-title-group>
<journal-title>PLOS Computational Biology</journal-title>
</journal-title-group>
<issn pub-type="ppub">1553-734X</issn>
<issn pub-type="epub">1553-7358</issn>
<publisher>
<publisher-name>Public Library of Science</publisher-name>
<publisher-loc>San Francisco, CA USA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="publisher-id">PCOMPBIOL-D-16-01078</article-id>
<article-id pub-id-type="doi">10.1371/journal.pcbi.1005216</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Research Article</subject>
</subj-group>
<subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Pharmaceutics</subject><subj-group><subject>Dose prediction methods</subject><subj-group><subject>Adjustment of dosage at steady state</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Cell biology</subject><subj-group><subject>Signal transduction</subject><subj-group><subject>Cell signaling</subject><subj-group><subject>Signaling cascades</subject><subj-group><subject>MAPK signaling cascades</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Biochemistry</subject><subj-group><subject>Enzymology</subject><subj-group><subject>Enzyme inhibitors</subject><subj-group><subject>Kinase inhibitors</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Biochemistry</subject><subj-group><subject>Enzymology</subject><subj-group><subject>Enzyme inhibitors</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Pharmacology</subject><subj-group><subject>Drug interactions</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Biochemistry</subject><subj-group><subject>Proteins</subject><subj-group><subject>Post-translational modification</subject><subj-group><subject>Phosphorylation</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Biochemistry</subject><subj-group><subject>Enzymology</subject><subj-group><subject>Enzyme chemistry</subject><subj-group><subject>Enzyme regulation</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Research and analysis methods</subject><subj-group><subject>Mathematical and statistical techniques</subject><subj-group><subject>Mathematical models</subject></subj-group></subj-group></subj-group></article-categories>
<title-group>
<article-title>Kinase Inhibition Leads to Hormesis in a Dual Phosphorylation-Dephosphorylation Cycle</article-title>
<alt-title alt-title-type="running-head">Kinase Inhibition and Hormesis</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Rashkov</surname> <given-names>Peter</given-names></name>
<xref ref-type="aff" rid="aff001"><sup>1</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Barrett</surname> <given-names>Ian P.</given-names></name>
<xref ref-type="aff" rid="aff002"><sup>2</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Beardmore</surname> <given-names>Robert E.</given-names></name>
<xref ref-type="aff" rid="aff001"><sup>1</sup></xref>
</contrib>
<contrib contrib-type="author" corresp="yes" xlink:type="simple">
<name name-style="western">
<surname>Bendtsen</surname> <given-names>Claus</given-names></name>
<xref ref-type="aff" rid="aff002"><sup>2</sup></xref>
<xref ref-type="corresp" rid="cor001">*</xref>
</contrib>
<contrib contrib-type="author" corresp="yes" xlink:type="simple">
<contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0003-3450-6854</contrib-id>
<name name-style="western">
<surname>Gudelj</surname> <given-names>Ivana</given-names></name>
<xref ref-type="aff" rid="aff001"><sup>1</sup></xref>
<xref ref-type="corresp" rid="cor001">*</xref>
</contrib>
</contrib-group>
<aff id="aff001">
<label>1</label>
<addr-line>School of Biosciences, University of Exeter, Exeter, United Kingdom</addr-line>
</aff>
<aff id="aff002">
<label>2</label>
<addr-line>Discovery Sciences, Innovative Medicines and Early Development, AstraZeneca, Cambridge, United Kingdom</addr-line>
</aff>
<contrib-group>
<contrib contrib-type="editor" xlink:type="simple">
<name name-style="western">
<surname>Pfeiffer</surname> <given-names>Thomas</given-names></name>
<role>Editor</role>
<xref ref-type="aff" rid="edit1"/>
</contrib>
</contrib-group>
<aff id="edit1">
<addr-line>Massey University, NEW ZEALAND</addr-line>
</aff>
<author-notes>
<fn fn-type="conflict" id="coi001">
<p>IPB and CB were employees of AstraZeneca at time of writing of the manuscript. This does not alter the authors’ adherence to PLOS policies on sharing data and materials.</p>
</fn>
<fn fn-type="con">
<p>
<list list-type="simple">
<list-item>
<p><bold>Conceptualization:</bold> IG CB IPB REB.</p>
</list-item>
<list-item>
<p><bold>Formal analysis:</bold> PR.</p>
</list-item>
<list-item>
<p><bold>Funding acquisition:</bold> IG REB.</p>
</list-item>
<list-item>
<p><bold>Methodology:</bold> PR IG IPB CB.</p>
</list-item>
<list-item>
<p><bold>Software:</bold> PR.</p>
</list-item>
<list-item>
<p><bold>Supervision:</bold> IG REB IPB CB.</p>
</list-item>
<list-item>
<p><bold>Writing – original draft:</bold> IG REB IPB CB PR.</p>
</list-item>
</list>
</p>
</fn>
<corresp id="cor001">* E-mail: <email xlink:type="simple">Claus.Bendtsen@astrazeneca.com</email> (CB); <email xlink:type="simple">I.Gudelj@exeter.ac.uk</email> (IG)</corresp>
</author-notes>
<pub-date pub-type="collection">
<month>11</month>
<year>2016</year>
</pub-date>
<pub-date pub-type="epub">
<day>29</day>
<month>11</month>
<year>2016</year>
</pub-date>
<volume>12</volume>
<issue>11</issue>
<elocation-id>e1005216</elocation-id>
<history>
<date date-type="received">
<day>4</day>
<month>7</month>
<year>2016</year>
</date>
<date date-type="accepted">
<day>21</day>
<month>10</month>
<year>2016</year>
</date>
</history>
<permissions>
<copyright-year>2016</copyright-year>
<copyright-holder>Rashkov et al</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/" xlink:type="simple">
<license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/" xlink:type="simple">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p>
</license>
</permissions>
<self-uri content-type="pdf" xlink:href="info:doi/10.1371/journal.pcbi.1005216"/>
<abstract>
<p>Many antimicrobial and anti-tumour drugs elicit hormetic responses characterised by low-dose stimulation and high-dose inhibition. While this can have profound consequences for human health, with low drug concentrations actually stimulating pathogen or tumour growth, the mechanistic understanding behind such responses is still lacking. We propose a novel, simple but general mechanism that could give rise to hormesis in systems where an inhibitor acts on an enzyme. At its core is one of the basic building blocks in intracellular signalling, the dual phosphorylation-dephosphorylation motif, found in diverse regulatory processes including control of cell proliferation and programmed cell death. Our analytically-derived conditions for observing hormesis provide clues as to why this mechanism has not been previously identified. Current mathematical models regularly make simplifying assumptions that lack empirical support but inadvertently preclude the observation of hormesis. In addition, due to the inherent population heterogeneities, the presence of hormesis is likely to be masked in empirical population-level studies. Therefore, examining hormetic responses at single-cell level coupled with improved mathematical models could substantially enhance detection and mechanistic understanding of hormesis.</p>
</abstract>
<abstract abstract-type="summary">
<title>Author Summary</title>
<p>Hormesis is a highly controversial and poorly understood phenomenon. It describes the idea that an inhibitor molecule, like an anti-cancer or anti-microbial drug, can inadvertently stimulate cell growth instead of suppressing it. This can have a profound effect on human health leading to failures in clinical treatments. Therefore, getting at the mechanistic basis of hormesis is critical for drug development and clinical practice, however molecular mechanisms underpinning hormesis remain poorly understood. In this paper we use a mathematical model to propose a simple and yet general mechanism that could explain why we find hormesis so widely in living systems. In particular, we discover that hormesis is present within a fundamental structure that forms a basic building block of many intracellular signalling pathways found in diverse processes including control of cell reproduction and programmed cell death. The benefits of our study are two-fold. Having simple molecular understanding of the causes of hormetic responses can greatly improve the design of new drug compounds that avoid such responses. Moreover, due to the fundamental nature of the newly proposed mechanism, our findings have a potential broad applicability to both anti-cancer and anti-microbial drugs.</p>
</abstract>
<funding-group>
<award-group id="award001">
<funding-source>
<institution-wrap>
<institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/501100000268</institution-id>
<institution>Biotechnology and Biological Sciences Research Council</institution>
</institution-wrap>
</funding-source>
<award-id>BB/J010340/1</award-id>
<principal-award-recipient>
<contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0003-3450-6854</contrib-id>
<name name-style="western">
<surname>Gudelj</surname> <given-names>Ivana</given-names></name>
</principal-award-recipient>
</award-group>
<award-group id="award002">
<funding-source>
<institution-wrap>
<institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/501100000266</institution-id>
<institution>Engineering and Physical Sciences Research Council</institution>
</institution-wrap>
</funding-source>
<award-id>EP/I00503X/1</award-id>
<principal-award-recipient>
<name name-style="western">
<surname>Beardmore</surname> <given-names>Robert E</given-names></name>
</principal-award-recipient>
</award-group>
<award-group id="award003">
<funding-source>
<institution-wrap>
<institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/100004440</institution-id>
<institution>Wellcome Trust</institution>
</institution-wrap>
</funding-source>
<award-id>ISSF Exeter University</award-id>
<principal-award-recipient>
<contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0003-3450-6854</contrib-id>
<name name-style="western">
<surname>Gudelj</surname> <given-names>Ivana</given-names></name>
</principal-award-recipient>
</award-group>
<funding-statement>Funding bodies: BBSRC (BB/J010340/1); EPSRC (EP/I00503X/1); Wellcome Trust (ISSF to University of Exeter). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</funding-statement>
</funding-group>
<counts>
<fig-count count="5"/>
<table-count count="0"/>
<page-count count="15"/>
</counts>
<custom-meta-group>
<custom-meta id="data-availability">
<meta-name>Data Availability</meta-name>
<meta-value>All data are contained in the paper and Supporting Information.</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
</front>
<body>
<sec id="sec001" sec-type="intro">
<title>Introduction</title>
<p>Hormesis is a phenomenon describing biphasic dose response relationships that exhibit low-dose stimulation and high-dose inhibition [<xref ref-type="bibr" rid="pcbi.1005216.ref001">1</xref>]. Many medical agents such as antibacterials, antifungals, and anti-tumour drugs have been found to display hormetic response [<xref ref-type="bibr" rid="pcbi.1005216.ref002">2</xref>] with the earliest observations dating back to 1800s. In particular, low concentrations of certain antifungals were found to stimulate fungal growth [<xref ref-type="bibr" rid="pcbi.1005216.ref003">3</xref>] or metabolism [<xref ref-type="bibr" rid="pcbi.1005216.ref004">4</xref>] while inducing toxicity at high concentrations. From the early 1920s the concept of low-dose stimulation and high-dose toxicity of various chemical elements with respect to bacterial growth was widely recognised [<xref ref-type="bibr" rid="pcbi.1005216.ref005">5</xref>]. We now know that bacteria can exhibit hormetic response to a wide range of antibiotic drugs, regardless of their mode of action [<xref ref-type="bibr" rid="pcbi.1005216.ref006">6</xref>]. This phenomenon is also found in tumour cells exposed to anti-tumour drugs. In fact, hormesis has been observed in an astonishingly broad range of tumour types including pancreatic, colon and breast (reviewed in [<xref ref-type="bibr" rid="pcbi.1005216.ref007">7</xref>]).</p>
<p>Despite the overwhelming body of research, some dating back a century, that documents hormetic responses to a broad range of compounds, their clinical significance has only relatively recently come to the fore [<xref ref-type="bibr" rid="pcbi.1005216.ref002">2</xref>]. The consequence of hormesis could have a profound effect for human health [<xref ref-type="bibr" rid="pcbi.1005216.ref008">8</xref>, <xref ref-type="bibr" rid="pcbi.1005216.ref009">9</xref>]. Drug concentration generally varies substantially within the human body and as drug gets cleared, the associated low concentration can in turn stimulate pathogen or tumour growth. Therefore understanding the mechanistic basis of hormesis is vital for both drug development and clinical practice.</p>
<p>The vast majority of targets for antibiotics, antifungals and anti-tumour drugs fall into the following categories: enzymes, receptors, transporters and DNA/RNA and the ribosome [<xref ref-type="bibr" rid="pcbi.1005216.ref010">10</xref>]. However how such drug-target interactions lead to hormesis remains poorly understood. The biological explanations put forward are overcompensation after a disruption of homeostasis (reviewed in [<xref ref-type="bibr" rid="pcbi.1005216.ref011">11</xref>]), direct stimulatory response [<xref ref-type="bibr" rid="pcbi.1005216.ref012">12</xref>], superimposition of different monotonic dose-response curves [<xref ref-type="bibr" rid="pcbi.1005216.ref013">13</xref>], or heterogenic susceptibility of different tissues to the same stimuli [<xref ref-type="bibr" rid="pcbi.1005216.ref014">14</xref>]. These explanations provide understanding of hormesis at a phenotypic level but lack understanding at the molecular level. Some inroads have also been made with respect to mammalian cells focusing on drug mechanisms mediated via receptor and/or cell signalling pathways (reviewed in [<xref ref-type="bibr" rid="pcbi.1005216.ref007">7</xref>]). For example, biphasic dose response could occur through interaction of two different receptor subtypes that mediate/activate opposing stimulatory and inhibitory pathways via the same antagonist [<xref ref-type="bibr" rid="pcbi.1005216.ref015">15</xref>]. However, hormetic response is a built in feature of such receptor mediated mechanisms rather than an emergent property of the underlying biological system.</p>
<p>An area of research where understanding of the mechanisms giving rise to hormesis is particularly lacking involves enzyme-targeting drugs. Known as enzyme inhibitors, they are designed to block enzyme activity leading to disruption of bacterial cell wall [<xref ref-type="bibr" rid="pcbi.1005216.ref016">16</xref>], fungal membranes [<xref ref-type="bibr" rid="pcbi.1005216.ref017">17</xref>] and fungal cell wall [<xref ref-type="bibr" rid="pcbi.1005216.ref018">18</xref>] as well as programmed tumour cell death [<xref ref-type="bibr" rid="pcbi.1005216.ref019">19</xref>], to name a few. With regards to hormetic dose-responses to antibiotics, a recent study focusing on inhibition of a specific enzyme, Dihydropteroate synthase, suggested the involvement of bacterial quorum sensing [<xref ref-type="bibr" rid="pcbi.1005216.ref020">20</xref>]. To our knowledge, mechanisms behind hormetic dose-response to enzyme-inhibiting antifungals are not known.</p>
<p>In recent years kinase inhibitors, a subset of enzyme inhibitors, have been shown to be very effective therapeutic agents in a broad range of diseases, including cancers. Amongst other enzyme inhibitors, significant attention has been focused on those inhibiting the <underline>m</underline>itogen-<underline>a</underline>ctivated <underline>p</underline>rotein <underline>k</underline>inase (MAPK) pathway [<xref ref-type="bibr" rid="pcbi.1005216.ref021">21</xref>–<xref ref-type="bibr" rid="pcbi.1005216.ref024">24</xref>], which is of fundamental importance to human health as abnormal regulations of MAPK contribute to tumour progression [<xref ref-type="bibr" rid="pcbi.1005216.ref025">25</xref>].</p>
<p>The observations of hormesis in MAPKs as a result of inhibition of BRAF oncogene are widespread: low doses of RAF inhibitors designed to cease tumour proliferation [<xref ref-type="bibr" rid="pcbi.1005216.ref026">26</xref>] can cause a paradoxical activation of tumour cell activity through undesired MAPK up-regulation [<xref ref-type="bibr" rid="pcbi.1005216.ref008">8</xref>, <xref ref-type="bibr" rid="pcbi.1005216.ref009">9</xref>, <xref ref-type="bibr" rid="pcbi.1005216.ref027">27</xref>–<xref ref-type="bibr" rid="pcbi.1005216.ref032">32</xref>]. Current explanations of hormetic responses induced by RAF kinase inhibition involve complex phenomena affecting regulatory mechanisms, feedback pathways or enzymatic activity [<xref ref-type="bibr" rid="pcbi.1005216.ref033">33</xref>], making them difficult to generalise. More generally, enzyme competition for the same substrate was recently proposed as a simpler mechanism giving rise to hormetic effects of enzyme-targeting Alzheimer’s drugs [<xref ref-type="bibr" rid="pcbi.1005216.ref034">34</xref>].</p>
<p>In this paper we put forward a novel, simple but general mechanism driving hormetic responses in systems where an inhibitor acts on an enzyme. We develop a mathematical model based on a basic building block in intracellular signalling, namely a dual phosphorylation-dephosphorylation motif, to which a kinase inhibitor is applied. In a broader context, dual-phosphorylation can be found in diverse processes such as circadian rhythms [<xref ref-type="bibr" rid="pcbi.1005216.ref035">35</xref>], virulence regulation [<xref ref-type="bibr" rid="pcbi.1005216.ref036">36</xref>, <xref ref-type="bibr" rid="pcbi.1005216.ref037">37</xref>], mitotic entry [<xref ref-type="bibr" rid="pcbi.1005216.ref038">38</xref>], transcription [<xref ref-type="bibr" rid="pcbi.1005216.ref039">39</xref>, <xref ref-type="bibr" rid="pcbi.1005216.ref040">40</xref>], cytokine production [<xref ref-type="bibr" rid="pcbi.1005216.ref040">40</xref>], as well as in MAPK pathways which regulate primary cellular activities in eukaryotes including proliferation and programmed cell death [<xref ref-type="bibr" rid="pcbi.1005216.ref041">41</xref>, <xref ref-type="bibr" rid="pcbi.1005216.ref042">42</xref>].</p>
<p>The model demonstrates that under certain conditions the steady state amount of the double-phosphorylated protein substrate in the cycle can substantially increase at low inhibitor doses compared to the base level without inhibition. Therefore the dose-response curve of the double-phosphorylated substrate possesses a hallmark of hormesis: it is upward sloping at low inhibitor doses and downward sloping at high inhibitor doses. The existence of hormesis in our model depends on the mechanism of inhibition and the dissociation rates of the kinase-substrate-inhibitor complexes. We also found that the magnitude of hormetic responses depends on the substrate-kinase ratio in a non-monotone way.</p>
<p>The benefits of our study are two-fold. Our mechanism is based on a principal component of intracellular signalling pathways, and as such has a potential broad applicability. Moreover having simple molecular understanding of the causes of hormetic responses can greatly improve the design of new drug compounds that avoid such responses.</p>
</sec>
<sec id="sec002" sec-type="materials|methods">
<title>Materials and Methods</title>
<sec id="sec003">
<title>The mathematical model</title>
<p>We consider a simple dual phosphorylation-dephosphorylation motif, whereby a distinct kinase protein is phosphorylating a separate protein substrate. Multiple phosphorylations can occur in close proximity or in diverse sites on a protein and here we focus on the former, instances of which can be found in activation of conventional MAPK enzymes [<xref ref-type="bibr" rid="pcbi.1005216.ref043">43</xref>], cell-cycle regulation via cyclin-dependent kinase 1 [<xref ref-type="bibr" rid="pcbi.1005216.ref044">44</xref>], regulation of other non-MAPK kinases [<xref ref-type="bibr" rid="pcbi.1005216.ref045">45</xref>] and ion channel trafficking [<xref ref-type="bibr" rid="pcbi.1005216.ref046">46</xref>]. The motif we consider is a subset of futile cycles [<xref ref-type="bibr" rid="pcbi.1005216.ref047">47</xref>, <xref ref-type="bibr" rid="pcbi.1005216.ref048">48</xref>] also known as a single stage module in the context of MAPK pathways [<xref ref-type="bibr" rid="pcbi.1005216.ref049">49</xref>, <xref ref-type="bibr" rid="pcbi.1005216.ref050">50</xref>]. Based on the experimental evidence for MAPK pathways [<xref ref-type="bibr" rid="pcbi.1005216.ref051">51</xref>–<xref ref-type="bibr" rid="pcbi.1005216.ref053">53</xref>] we assume that our motif follows a distributive mechanism consisting of two sequential phosphorylation steps and two sequential dephosphorylation steps that share the same intermediate mono-phosphorylated form. In particular, the protein substrate (C) is first converted into a mono-phosphorylated form (C<sub>P</sub>) and subsequently into a double-phosphorylated form (C<sub>PP</sub>), through a chain of reactions facilitated by a kinase (kin). Conversely C<sub>PP</sub> is converted back to C<sub>P</sub> which is subsequently converted to C, through a chain of reactions facilitated by a phosphatase (pho). In the distributive mechanism, the kinase(phosphatase) facilitates at most one phosphorylation (dephosphorylation) in each molecular encounter [<xref ref-type="bibr" rid="pcbi.1005216.ref048">48</xref>].</p>
<p>Therefore our dual phosphorylation-dephosphorylation motif can be described by the following reaction kinetic equations, which are a simplification of the reaction scheme described in [<xref ref-type="bibr" rid="pcbi.1005216.ref054">54</xref>]:
<disp-formula id="pcbi.1005216.e001"><alternatives><graphic id="pcbi.1005216.e001g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1005216.e001" xlink:type="simple"/><mml:math display="block" id="M1"><mml:mtable columnalign="left"><mml:mtr columnalign="left"><mml:mtd columnalign="right"><mml:mrow><mml:mtext>C</mml:mtext><mml:mo>+</mml:mo><mml:mtext>kin</mml:mtext></mml:mrow></mml:mtd><mml:mtd columnalign="left"><mml:mrow><mml:munderover><mml:mo>⇌</mml:mo><mml:mrow><mml:msub><mml:mi>k</mml:mi><mml:mrow><mml:mo>−</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:msub><mml:mi>k</mml:mi><mml:mn>1</mml:mn></mml:msub></mml:mrow></mml:munderover></mml:mrow></mml:mtd><mml:mtd columnalign="left"><mml:mrow><mml:mtext>C</mml:mtext><mml:mo>·</mml:mo><mml:mtext>kin</mml:mtext><mml:mover><mml:mo>→</mml:mo><mml:mrow><mml:msub><mml:mi>k</mml:mi><mml:mn>2</mml:mn></mml:msub></mml:mrow></mml:mover><mml:msub><mml:mtext>C</mml:mtext><mml:mtext>P</mml:mtext></mml:msub><mml:mo>+</mml:mo><mml:mtext>kin</mml:mtext><mml:mo>,</mml:mo></mml:mrow></mml:mtd></mml:mtr><mml:mtr columnalign="left"><mml:mtd columnalign="right"><mml:mrow><mml:msub><mml:mtext>C</mml:mtext><mml:mtext>P</mml:mtext></mml:msub><mml:mo>+</mml:mo><mml:mtext>kin</mml:mtext></mml:mrow></mml:mtd><mml:mtd columnalign="left"><mml:mrow><mml:munderover><mml:mo>⇌</mml:mo><mml:mrow><mml:msub><mml:mi>k</mml:mi><mml:mrow><mml:mo>−</mml:mo><mml:mn>3</mml:mn></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:msub><mml:mi>k</mml:mi><mml:mn>3</mml:mn></mml:msub></mml:mrow></mml:munderover></mml:mrow></mml:mtd><mml:mtd columnalign="left"><mml:mrow><mml:msub><mml:mtext>C</mml:mtext><mml:mtext>P</mml:mtext></mml:msub><mml:mo>·</mml:mo><mml:mtext>kin</mml:mtext><mml:mover><mml:mo>→</mml:mo><mml:mrow><mml:msub><mml:mi>k</mml:mi><mml:mn>4</mml:mn></mml:msub></mml:mrow></mml:mover><mml:msub><mml:mtext>C</mml:mtext><mml:mrow><mml:mtext>PP</mml:mtext></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:mtext>kin</mml:mtext><mml:mo>,</mml:mo></mml:mrow></mml:mtd></mml:mtr><mml:mtr columnalign="left"><mml:mtd columnalign="right"><mml:mrow><mml:msub><mml:mtext>C</mml:mtext><mml:mrow><mml:mtext>PP</mml:mtext></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:mtext>pho</mml:mtext></mml:mrow></mml:mtd><mml:mtd columnalign="left"><mml:mrow><mml:munderover><mml:mo>⇌</mml:mo><mml:mrow><mml:msub><mml:mi>k</mml:mi><mml:mrow><mml:mo>−</mml:mo><mml:mn>5</mml:mn></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:msub><mml:mi>k</mml:mi><mml:mn>5</mml:mn></mml:msub></mml:mrow></mml:munderover></mml:mrow></mml:mtd><mml:mtd columnalign="left"><mml:mrow><mml:msub><mml:mtext>C</mml:mtext><mml:mtext>PP</mml:mtext></mml:msub><mml:mo>·</mml:mo><mml:mtext>pho</mml:mtext><mml:mover><mml:mo>→</mml:mo><mml:mrow><mml:msub><mml:mi>k</mml:mi><mml:mn>6</mml:mn></mml:msub></mml:mrow></mml:mover><mml:msub><mml:mtext>C</mml:mtext><mml:mtext>P</mml:mtext></mml:msub><mml:mo>+</mml:mo><mml:mtext>pho</mml:mtext><mml:mo>,</mml:mo></mml:mrow></mml:mtd></mml:mtr><mml:mtr columnalign="left"><mml:mtd columnalign="right"><mml:mrow><mml:msub><mml:mtext>C</mml:mtext><mml:mtext>P</mml:mtext></mml:msub><mml:mo>+</mml:mo><mml:mtext>pho</mml:mtext></mml:mrow></mml:mtd><mml:mtd columnalign="left"><mml:mrow><mml:munderover><mml:mo>⇌</mml:mo><mml:mrow><mml:msub><mml:mi>k</mml:mi><mml:mrow><mml:mo>−</mml:mo><mml:mn>7</mml:mn></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:msub><mml:mi>k</mml:mi><mml:mn>7</mml:mn></mml:msub></mml:mrow></mml:munderover></mml:mrow></mml:mtd><mml:mtd columnalign="left"><mml:mrow><mml:msub><mml:mtext>C</mml:mtext><mml:mtext>P</mml:mtext></mml:msub><mml:mo>·</mml:mo><mml:mtext>pho</mml:mtext><mml:mover><mml:mo>→</mml:mo><mml:mrow><mml:msub><mml:mi>k</mml:mi><mml:mn>8</mml:mn></mml:msub></mml:mrow></mml:mover><mml:mtext>C</mml:mtext><mml:mo>+</mml:mo><mml:mtext>pho</mml:mtext><mml:mo>.</mml:mo></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:math>
</alternatives> <label>(1)</label></disp-formula>
Next we describe the assumptions behind the introduction of an inhibitor into <xref ref-type="disp-formula" rid="pcbi.1005216.e001">Eq (1)</xref>, based on the general modifier mechanism also known as hyperbolic or partial competitive inhibition [<xref ref-type="bibr" rid="pcbi.1005216.ref055">55</xref>]. We assume that the inhibitor (inh) is able to react with the kinase and the substrate-kinase intermediate complexes C · kin and C<sub>P</sub> · kin according to the following inhibition scheme:
<disp-formula id="pcbi.1005216.e002"><alternatives><graphic id="pcbi.1005216.e002g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1005216.e002" xlink:type="simple"/><mml:math display="block" id="M2"><mml:mtable columnalign="left"><mml:mtr columnalign="left"><mml:mtd columnalign="right"><mml:mrow><mml:mtext>kin</mml:mtext><mml:mo>+</mml:mo><mml:mtext>inh</mml:mtext></mml:mrow></mml:mtd><mml:mtd columnalign="left"><mml:mrow><mml:munderover><mml:mo>⇌</mml:mo><mml:mrow><mml:msub><mml:mi>d</mml:mi><mml:mi>r</mml:mi></mml:msub></mml:mrow><mml:mrow><mml:msub><mml:mi>d</mml:mi><mml:mi>f</mml:mi></mml:msub></mml:mrow></mml:munderover></mml:mrow></mml:mtd><mml:mtd columnalign="left"><mml:mrow><mml:mtext>kin</mml:mtext><mml:mo>·</mml:mo><mml:mtext>inh</mml:mtext><mml:mo>,</mml:mo></mml:mrow></mml:mtd></mml:mtr><mml:mtr columnalign="left"><mml:mtd columnalign="right"><mml:mrow><mml:mtext>C</mml:mtext><mml:mo>·</mml:mo><mml:mtext>kin</mml:mtext><mml:mo>+</mml:mo><mml:mtext>inh</mml:mtext></mml:mrow></mml:mtd><mml:mtd columnalign="left"><mml:mrow><mml:munderover><mml:mo>⇌</mml:mo><mml:mrow><mml:msub><mml:mi>e</mml:mi><mml:mrow><mml:mo>−</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:msub><mml:mi>e</mml:mi><mml:mn>1</mml:mn></mml:msub></mml:mrow></mml:munderover></mml:mrow></mml:mtd><mml:mtd columnalign="left"><mml:mrow><mml:mtext>C</mml:mtext><mml:mo>·</mml:mo><mml:mtext>kin</mml:mtext><mml:mo>·</mml:mo><mml:mtext>inh</mml:mtext><mml:munderover><mml:mo>⇌</mml:mo><mml:mrow><mml:msub><mml:mi>e</mml:mi><mml:mrow><mml:mo>−</mml:mo><mml:mn>2</mml:mn></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:msub><mml:mi>e</mml:mi><mml:mn>2</mml:mn></mml:msub></mml:mrow></mml:munderover><mml:mtext>C</mml:mtext><mml:mo>+</mml:mo><mml:mtext>kin</mml:mtext><mml:mo>·</mml:mo><mml:mtext>inh</mml:mtext><mml:mo>,</mml:mo></mml:mrow></mml:mtd></mml:mtr><mml:mtr columnalign="left"><mml:mtd columnalign="right"><mml:mrow><mml:msub><mml:mtext>C</mml:mtext><mml:mtext>P</mml:mtext></mml:msub><mml:mo>·</mml:mo><mml:mtext>kin</mml:mtext><mml:mo>+</mml:mo><mml:mtext>inh</mml:mtext></mml:mrow></mml:mtd><mml:mtd columnalign="left"><mml:mrow><mml:munderover><mml:mo>⇌</mml:mo><mml:mrow><mml:msub><mml:mi>e</mml:mi><mml:mrow><mml:mo>−</mml:mo><mml:mn>3</mml:mn></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:msub><mml:mi>e</mml:mi><mml:mn>3</mml:mn></mml:msub></mml:mrow></mml:munderover></mml:mrow></mml:mtd><mml:mtd columnalign="left"><mml:mrow><mml:msub><mml:mtext>C</mml:mtext><mml:mtext>P</mml:mtext></mml:msub><mml:mo>·</mml:mo><mml:mtext>kin</mml:mtext><mml:mo>·</mml:mo><mml:mtext>inh</mml:mtext><mml:munderover><mml:mo>⇌</mml:mo><mml:mrow><mml:msub><mml:mi>e</mml:mi><mml:mrow><mml:mo>−</mml:mo><mml:mn>4</mml:mn></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:msub><mml:mi>e</mml:mi><mml:mn>4</mml:mn></mml:msub></mml:mrow></mml:munderover><mml:msub><mml:mtext>C</mml:mtext><mml:mtext>P</mml:mtext></mml:msub><mml:mo>+</mml:mo><mml:mtext>kin</mml:mtext><mml:mo>·</mml:mo><mml:mtext>inh</mml:mtext><mml:mo>.</mml:mo></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:math></alternatives> <label>(2)</label></disp-formula>
The first- and second-order rates <italic>k</italic><sub><italic>i</italic></sub> and <italic>e</italic><sub><italic>i</italic></sub> in Eqs <xref ref-type="disp-formula" rid="pcbi.1005216.e001">(1)</xref> and <xref ref-type="disp-formula" rid="pcbi.1005216.e002">(2)</xref> and the association and dissociation rates <italic>d</italic><sub><italic>f</italic></sub> and <italic>d</italic><sub><italic>r</italic></sub> in <xref ref-type="disp-formula" rid="pcbi.1005216.e002">Eq (2)</xref> are considered dimensionless. In our system intermediate substrate-kinase-inhibitor complexes are able to dissociate into a substrate and kinase-inhibitor complex with forward <italic>e</italic><sub>2</sub>, <italic>e</italic><sub>4</sub> and backward <italic>e</italic><sub>−2</sub>, <italic>e</italic><sub>−4</sub> rates [<xref ref-type="bibr" rid="pcbi.1005216.ref056">56</xref>].</p>
<p>The model describing the time evolution of the substrate, kinase, phosphatase and inhibitor concentrations is based on the law of mass action and assumes the total conservation of mass holds for all four compounds. The details of the system of 9 differential equations and the corresponding analysis are presented in <xref ref-type="supplementary-material" rid="pcbi.1005216.s001">S1 Appendix</xref>. (with Supplementary Tables A1 and A2 containing model parameter values). This model system is studied under steady state conditions, that is, when all concentrations of reactants have reached a dynamic equilibrium. Numerical simulations are conducted with Matcont, a continuation package in MATLAB used for numerical bifurcation analysis of ODEs [<xref ref-type="bibr" rid="pcbi.1005216.ref057">57</xref>].</p>
</sec>
</sec>
<sec id="sec004" sec-type="results">
<title>Results</title>
<p>In the absence of an inhibitor, the double phosphorylation motif <xref ref-type="disp-formula" rid="pcbi.1005216.e001">Eq (1)</xref> can possess either a single or two stable steady states of the doubly-phosphorylated form of the substrate C<sub>PP</sub>, [<xref ref-type="bibr" rid="pcbi.1005216.ref050">50</xref>, <xref ref-type="bibr" rid="pcbi.1005216.ref054">54</xref>, <xref ref-type="bibr" rid="pcbi.1005216.ref058">58</xref>, <xref ref-type="bibr" rid="pcbi.1005216.ref059">59</xref>]. Therefore in our study we consider two cases: first, when the motif <xref ref-type="disp-formula" rid="pcbi.1005216.e001">Eq (1)</xref> is monostable and second, when this motif is bi-stable.</p>
<p>In the case of a single stable steady state (C<sub>PP</sub>*) in the absence of an inhibitor, we find that C<sub>PP</sub> can exhibit biphasic (or hormetic) response to an inhibitor as illustrated in <xref ref-type="fig" rid="pcbi.1005216.g001">Fig 1</xref>. In particular, the observed dose-response curve in the presence of an inhibitor has an inverted U-shape: for sufficiently low inhibitor doses the computed steady-state values of C<sub>PP</sub> increase monotonically, while for sufficiently large inhibitor doses, the computed steady-state values of C<sub>PP</sub> monotonically decrease.</p>
<fig id="pcbi.1005216.g001" position="float">
<object-id pub-id-type="doi">10.1371/journal.pcbi.1005216.g001</object-id>
<label>Fig 1</label>
<caption>
<title>Dose response curve (log scale) for the double-phosphorylated substrate C<sub>PP</sub> in the presence of an inhibitor (inh<sub>tot</sub>), in the case when the motif <xref ref-type="disp-formula" rid="pcbi.1005216.e001">Eq (1)</xref> is monostable.</title>
<p>In the absence of the inhibitor the stable steady state value of the double-phosphorylated substrate is denoted by C<sub>PP</sub>*. With the inhibitor present, the dose response exhibits hormetic properties whereby for sufficiently low inhibitor doses (inh<sub>tot</sub>&lt;inh*) the computed steady state values of C<sub>PP</sub> increase monotonically, before monotonically decreasing for inhibitor concentrations inh<sub>tot</sub>&gt;inh*. The magnitude of hormetic response is calculated as a difference between the C<sub>PP</sub> value at inh* and C<sub>PP</sub>*.</p>
</caption>
<graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1005216.g001" xlink:type="simple"/>
</fig>
<p>Moreover, by making simplifying assumptions that <italic>e</italic><sub>−2</sub> = <italic>e</italic><sub>−4</sub> = 0, <italic>e</italic><sub>2</sub> &gt;&gt;<italic>e</italic><sub>1</sub>, <italic>e</italic><sub>4</sub> &gt;&gt;<italic>e</italic><sub>3</sub> and the inhibitor has fast off rate, we can analytically derive the slope of the dose-response curve, in other words the slope of the relationship between the steady-state value of C<sub>PP</sub> and the total amount of inhibitor at low doses (see <xref ref-type="supplementary-material" rid="pcbi.1005216.s001">S1 Appendix</xref> for details). This allows us to identify two primary factors necessary for the hormesis to be observed:</p>
<list list-type="simple">
<list-item>
<p>(C1) the strong dissociation effect of intermediate substrate-kinase-inhibitor complexes C · kin · inh and C<sub>P</sub> · kin · inh, corresponding to <italic>e</italic><sub>2</sub>, <italic>e</italic><sub>4</sub> &gt; 0,</p>
</list-item>
<list-item>
<p>(C2) large dissociation rate of kinase-inhibitor complexes.</p>
</list-item>
</list>
<p>Note that the hormesis is still observed in numerical simulations when <italic>e</italic><sub>−2</sub>, <italic>e</italic><sub>−4</sub> &gt; 0 (Fig A1 in <xref ref-type="supplementary-material" rid="pcbi.1005216.s001">S1 Appendix</xref>).</p>
<p>In addition the above conditions (C1-C2) can also be used to forecast the presence of a hormetic dose response in the second case under our consideration, namely when in the absence of an inhibitor the motif <xref ref-type="disp-formula" rid="pcbi.1005216.e001">Eq (1)</xref> has two stable steady states C<sub>PP,1</sub>* (<xref ref-type="fig" rid="pcbi.1005216.g002">Fig 2A</xref>) and C<sub>PP,2</sub>* (<xref ref-type="fig" rid="pcbi.1005216.g002">Fig 2B</xref>). In this case the numerical simulations predict that cells with high base level of double-phosphorylated substrate will respond differently to inhibition from the cells with low base level of double-phosphorylated substrate. In particular, cells with initially high levels of C<sub>PP</sub> (at steady state C<sub>PP,1</sub>*) will exhibit a monotone decreasing dose-response (<xref ref-type="fig" rid="pcbi.1005216.g002">Fig 2A</xref>) while cells with low initial levels of C<sub>PP</sub> (at steady state C<sub>PP,2</sub>*) will exhibit a hormetic response (<xref ref-type="fig" rid="pcbi.1005216.g002">Fig 2B</xref>).</p>
<fig id="pcbi.1005216.g002" position="float">
<object-id pub-id-type="doi">10.1371/journal.pcbi.1005216.g002</object-id>
<label>Fig 2</label>
<caption>
<title>Dose response curve (log scale) for the double-phosphorylated substrate C<sub>PP</sub> in the presence of an inhibitor (inh<sub>tot</sub>), in the case when the motif <xref ref-type="disp-formula" rid="pcbi.1005216.e001">Eq (1)</xref> is bistable.</title>
<p>In the absence of the inhibitor there are two stable steady states of the double-phosphorylated substrate (A) C<sub>PP,1</sub>* and (B) C<sub>PP,2</sub>*. Cell populations at these two steady state will react differently to the presence of an inhibitor: (A) cells at C<sub>PP,1</sub>* will exhibit a monotone dose-response while (B) cells at C<sub>PP,2</sub>* will exhibit a hormetic dose response whereby for sufficiently low inhibitor doses (inh<sub>tot</sub>&lt;inh*) the computed steady state values of C<sub>PP</sub> increase monotonically, before monotonically decreasing for inhibitor concentrations inh<sub>tot</sub>&gt;inh*. The dotted lines indicate a discontinuous jump in the steady state values of C<sub>PP</sub> in the presence of the inhibitor. The magnitude of hormetic response is calculated as a difference between the C<sub>PP</sub> value at inh* and C<sub>PP,2</sub>*.</p>
</caption>
<graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1005216.g002" xlink:type="simple"/>
</fig>
<p>The magnitude of hormetic response can differ between the mono- and bi-stable cases under consideration as illustrated in Figs <xref ref-type="fig" rid="pcbi.1005216.g001">1</xref> and <xref ref-type="fig" rid="pcbi.1005216.g002">2B</xref>. In the mono-stable case the C<sub>PP</sub> value at dose inh* is approximately two-fold higher compared to the base level C<sub>PP</sub>* value in the absence of an inhibitor (<xref ref-type="fig" rid="pcbi.1005216.g001">Fig 1</xref>). In the bi-stable case the C<sub>PP</sub> value at dose inh* is approximately six-fold higher than the base level C<sub>PP,2</sub>* value in the absence of an inhibitor (<xref ref-type="fig" rid="pcbi.1005216.g002">Fig 2B</xref>).</p>
<p>In general, we find that the ratio of total mass of protein substrate to kinase mass influences the magnitude of hormetic response in a non-monotone way as shown in <xref ref-type="fig" rid="pcbi.1005216.g003">Fig 3</xref>. For sufficiently small substrate-kinase ratio, a hormetic response is not observed (absence of hormesis is labelled as 100% response in <xref ref-type="fig" rid="pcbi.1005216.g003">Fig 3</xref> because the maximal response is equal to the baseline of no inhibition). However, the hormetic response increases sharply as the substrate-kinase ratio increases. Further increases of this ratio lead to a sharp decline in the magnitude of hormetic response, which continues to increase slowly for sufficiently large substrate-kinase ratios (see <xref ref-type="fig" rid="pcbi.1005216.g003">Fig 3</xref> inset). Therefore, the magnitude of hormetic response peaks at intermediate values of the substrate-kinase ratio, as frequently observed in the MAPK pathway [<xref ref-type="bibr" rid="pcbi.1005216.ref060">60</xref>] for example, while hormesis is not observed for low substrate-kinase ratios.</p>
<fig id="pcbi.1005216.g003" position="float">
<object-id pub-id-type="doi">10.1371/journal.pcbi.1005216.g003</object-id>
<label>Fig 3</label>
<caption>
<title>Maximum hormetic response.</title>
<p>The maximum hormetic response is calculated as the maximal increase in C<sub>PP</sub> over all inhibitor doses, relative to the base line amount of C<sub>PP</sub> in the absence of inhibition. Since the baseline is represented at a level of 100%, hormesis is present if the maximum response strictly exceeds the baseline (&gt; 100%). This maximum response is plotted (black dots) as a function of different substrate-kinase ratios achieved by varying the total mass of substrate and keeping the total mass of kinase constant.</p>
</caption>
<graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1005216.g003" xlink:type="simple"/>
</fig>
</sec>
<sec id="sec005" sec-type="conclusions">
<title>Discussion</title>
<p>Hormetic responses to enzyme-targeting drugs have been observed in both prokaryotes [<xref ref-type="bibr" rid="pcbi.1005216.ref020">20</xref>, <xref ref-type="bibr" rid="pcbi.1005216.ref061">61</xref>, <xref ref-type="bibr" rid="pcbi.1005216.ref062">62</xref>] and eukaryotes [<xref ref-type="bibr" rid="pcbi.1005216.ref008">8</xref>, <xref ref-type="bibr" rid="pcbi.1005216.ref009">9</xref>, <xref ref-type="bibr" rid="pcbi.1005216.ref027">27</xref>, <xref ref-type="bibr" rid="pcbi.1005216.ref031">31</xref>, <xref ref-type="bibr" rid="pcbi.1005216.ref032">32</xref>] but the mechanistic understanding behind such responses is still lacking. In this paper we focus on eukaryotic cells and propose a novel, simple but general mechanism that could give rise to hormesis in systems where an inhibitor acts on an enzyme.</p>
<p>At the core of our newly-proposed mechanism is one of the basic building blocks in intracellular signalling, the dual phosphorylation-dephosphorylation motif, found in diverse regulatory processes including MAPK pathways which control cell proliferation and programmed cell death in eukaryotes [<xref ref-type="bibr" rid="pcbi.1005216.ref041">41</xref>, <xref ref-type="bibr" rid="pcbi.1005216.ref042">42</xref>]. We analytically derive conditions that lead to hormetic dose-response of the doubly-phosphorylated substrate in the presence of a kinase inhibitor. The conditions required for hormesis to be observed are surprisingly simple and involve two main factors: (C1) strong dissociation effect of intermediate substrate-kinase-inhibitor complexes and (C2) large dissociation rate of kinase-inhibitor complexes.</p>
<p>Crystallographic studies of kinase inhibitors bound to their targets demonstrate that a number of different conformational states can be induced. Type 1 kinase inhibitors are defined as binding the kinase in its active conformation and crystal structures of ternary complexes of ATP analogues bound with substrate peptides are reported (for review see [<xref ref-type="bibr" rid="pcbi.1005216.ref063">63</xref>, <xref ref-type="bibr" rid="pcbi.1005216.ref064">64</xref>]). Indeed it is not uncommon for crystal systems of substrate peptide complexes to be used in Structure Based Design campaigns to develop Type 1 kinase inhibitors [<xref ref-type="bibr" rid="pcbi.1005216.ref065">65</xref>].</p>
<p>Given the fundamental nature of the dual phosphorylation-dephosphorylation motif and the relative simplicity of the derived conditions necessary to observe hormesis, why was this mechanism previously overlooked in theoretical literature? A further examination of the (C1) condition could provide a potential answer. In general, when considering partial competitive enzyme inhibition [<xref ref-type="bibr" rid="pcbi.1005216.ref055">55</xref>] as we do here, classical enzyme kinetics literature [<xref ref-type="bibr" rid="pcbi.1005216.ref055">55</xref>, <xref ref-type="bibr" rid="pcbi.1005216.ref056">56</xref>] assumes not only equilibrium concentrations of different enzyme species but it also assumes that at those equilibrium concentrations there is no flux through substrate-kinase-inhibitor complexes. However, we find that in our study as flux decreases the maximum hormetic response also decreases (<xref ref-type="fig" rid="pcbi.1005216.g004">Fig 4</xref>) indicating that under the no-flux assumption, hormetic responses could be overlooked.</p>
<fig id="pcbi.1005216.g004" position="float">
<object-id pub-id-type="doi">10.1371/journal.pcbi.1005216.g004</object-id>
<label>Fig 4</label>
<caption>
<title>Relationship between the maximum hormetic response and the flux C · kin · inh → C + inh · kin.</title>
<p>The maximum hormetic response is calculated as the maximal increase in C<sub>PP</sub> over all inhibitor doses, relative to the base line amount of C<sub>PP</sub> in the absence of inhibition. Since the baseline is represented at a level of 100%, hormesis is present if the maximum response strictly exceeds the baseline (&gt; 100%). The flux is computed as <italic>e</italic><sub>2</sub>[C · kin · inh] − <italic>e</italic><sub>−2</sub>[C][kin · inh] using the steady state values [C](inh*), [kin · inh](inh*), [C · kin · inh](inh*) with inh* being the dose with the maximum hormetic response (see <xref ref-type="fig" rid="pcbi.1005216.g001">Fig 1</xref>). As <italic>e</italic><sub>−2</sub> increases, the flux decreases to 0.</p>
</caption>
<graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1005216.g004" xlink:type="simple"/>
</fig>
<p>Once a new mechanism is proposed to explain a particular biological phenomenon, ideally it should be put to test. However, there are a number of difficulties associated with <italic>in vitro</italic> tests of our model predictions. First, biochemical assays involved with <italic>in vitro</italic> studies are not standardised and vary between research groups, making comparisons between already published observations difficult. Second, testing our model predictions requires measurements of single and double phosphorylation outputs, this could be problematic as antibody specificity required to distinguish these outputs might not readily be available. This would particularly be relevant for systems where phosphorylation sites are situated close together. Third, ensuring that the condition for observing hormesis <italic>e</italic><sub>2</sub>, <italic>e</italic><sub>4</sub> &gt; 0 is satisfied experimentally is challenging as kinase biochemical assays would not usually include phosphatase activity. Furthermore varying rates of reactions individually or measuring fluxes in such systems is equally difficult.</p>
<p>Having discussed difficulties associated with testing our model in reductionist <italic>in vitro</italic> systems, we next consider whether these difficulties could be overcome with a cell-based experimental systems. In particular, our model predicts that hormetic dose-response could be a wide-spread feature of MAPK pathways when exposed to enzyme inhibitors. However we argue here that the non-trivial biphasic dose-response associated with hormesis might often be overlooked when performing experiments at cell population level, as we now discuss.</p>
<p>Consider the case where in the absence of an inhibitor, the double phosphorylation motif <xref ref-type="disp-formula" rid="pcbi.1005216.e001">Eq (1)</xref> possesses two stable steady states of the doubly-phosphorylated form of the substrate C<sub>PP</sub>. This means that tumour cells within a population can be grouped into two types: type-1 cells with ‘high’ C<sub>PP</sub> and type-2 cells with ‘low’ C<sub>PP</sub>. In reality these heterogeneous cell phenotypes can emerge not only due to multistability of the system [<xref ref-type="bibr" rid="pcbi.1005216.ref050">50</xref>, <xref ref-type="bibr" rid="pcbi.1005216.ref054">54</xref>] but also due to stochastic fluctuations which lead to different concentrations of the the total protein substrate [<xref ref-type="bibr" rid="pcbi.1005216.ref066">66</xref>, <xref ref-type="bibr" rid="pcbi.1005216.ref067">67</xref>]. In general, an untreated tumour is likely to harbour different proportions of cells in different phenotypic states [<xref ref-type="bibr" rid="pcbi.1005216.ref068">68</xref>].</p>
<p>We show that different cell types can respond differently to the presence of an inhibitor. Namely, our model predicts that in certain cases cells with initially high levels of C<sub>PP</sub> (at steady state C<sub>PP,1</sub>*) will exhibit a monotone decreasing dose-response (<xref ref-type="fig" rid="pcbi.1005216.g002">Fig 2A</xref>) while cells with low initial levels of C<sub>PP</sub> (at steady state C<sub>PP,2</sub>*) will exhibit a hormetic response (<xref ref-type="fig" rid="pcbi.1005216.g002">Fig 2B</xref>). This has an important consequence for measuring C<sub>PP</sub> at a population level as it is frequently done [<xref ref-type="bibr" rid="pcbi.1005216.ref069">69</xref>], as well as determining inhibitory concentrations (IC). Such consequences are best illustrated with the following example.</p>
<p>Let us assume, for example, that 88% of the tumour cells are type-1 cells and 12% of the tumour cells are type-2 cells. We can then simulate our model to generate dose response curves of C<sub>PP</sub> for both type-1 (<xref ref-type="fig" rid="pcbi.1005216.g005">Fig 5</xref>, green line) and type-2 (<xref ref-type="fig" rid="pcbi.1005216.g005">Fig 5</xref>, blue line) phenotypes. In addition, we can also numerically generate sampled values of the combined dose response of the entire population as would be measured, for instance, in a western blot or population-based imaging assay for C <sub>PP</sub> (<xref ref-type="fig" rid="pcbi.1005216.g005">Fig 5</xref>, red dots). By fitting a logistic curve to the sampled values of the combined dose response (<xref ref-type="fig" rid="pcbi.1005216.g005">Fig 5</xref>, red dashed line) we can estimate the inhibitor concentration causing 50% inhibition of the entire population, denoted IC<sub>50</sub>. However, the same inhibitor concentration has the opposing effects on the two sub-populations: while it inhibits type-1 cells, it actually stimulates type-2 cells. This can be observed by comparing steady-state values of C<sub>PP</sub> in the absence of inhibition (C<sub>PP,1</sub>* for type-1 and C<sub>PP,2</sub>* for type 2) to the steady-state values of C<sub>PP</sub> in the presence of the inhibitor (C<sub>PP,1</sub>** for type-1 and C<sub>PP,2</sub>** for type 2) at the IC<sub>50</sub> concentration estimated for the entire population (<xref ref-type="fig" rid="pcbi.1005216.g005">Fig 5</xref>). In particular, the inhibition of type-1 cells can be seen from C<sub>PP,1</sub>*&gt;C<sub>PP,1</sub>** while the stimulation of type-2 cells can be seen from C<sub>PP,2</sub>*&lt;C<sub>PP,2</sub>**. Such unexpected stimulatory effects of the population-level IC<sub>50</sub> exerted on type-2 sub-population could be further amplified when taking into account the imperfect drug penetration in a tumour [<xref ref-type="bibr" rid="pcbi.1005216.ref070">70</xref>]. In that case tumour cells would actually experience a lower inhibitor concentration IC*&lt;IC<sub>50</sub>, which could lead to significant increases in steady-state values of C<sub>PP</sub> (denoted by C<sub>PP,2</sub><sup><monospace>x</monospace></sup> in <xref ref-type="fig" rid="pcbi.1005216.g005">Fig 5</xref>), compared to the steady-state values of C<sub>PP</sub> in the absence of inhibition (denoted by C<sub>PP,2</sub>* in <xref ref-type="fig" rid="pcbi.1005216.g005">Fig 5</xref>). A numerical example with balanced type-1 and type-2 cell populations is presented in Fig A5 of <xref ref-type="supplementary-material" rid="pcbi.1005216.s001">S1 Appendix</xref>, showing that in this case it is also possible to mask the hormetic response at the population level, although the maximal hormetic response of the type-2 cells at the corresponding IC<sub>50</sub> is substantially lower.</p>
<fig id="pcbi.1005216.g005" position="float">
<object-id pub-id-type="doi">10.1371/journal.pcbi.1005216.g005</object-id>
<label>Fig 5</label>
<caption>
<title>Heterogeneous populations.</title>
<p>Dose response curves of type-1 (green line) and type-2 (blue line) cells in the presence of an inhibitor (inh<sub>tot</sub>), in the case when motif <xref ref-type="disp-formula" rid="pcbi.1005216.e001">Eq (1)</xref> is bistable. A logistic curve (red line) is fitted to sample points (red dots) generated numerically from a population containing 88% type-1 cells and 12% type-2 cells. The logistic fit to data is used to estimate IC<sub>50</sub> of the total population (see Supplementary Information). In the absence of the inhibitor type-1 cells are at C<sub>PP,1</sub>* stead state while type-2 cells are at C<sub>PP,2</sub>*. In the presence of the inhibitor at IC<sub>50</sub>, while the total population exhibits 50% inhibition, the same concentration has the opposing effects on the two sub-populations. In particular, type-1 cells are inhibited, which can be deduced from the observation that the steady state C<sub>PP,1</sub>** calculated at the population-level IC<sub>50</sub> is lower than the steady state C<sub>PP,1</sub>* calculated in the absence of the inhibitor. Contrary to this type-2 cells are stimulated since the steady state C<sub>PP,2</sub>** calculated at the population-level IC<sub>50</sub> is higher than the steady state C<sub>PP,2</sub>* calculated in the absence of the inhibitor. This stimulatory effect is amplified even further for IC*&lt;IC<sub>50</sub>, as seen by comparing the relatively high values of the steady state C<sub>PP,2</sub><sup><monospace>x</monospace></sup> at IC* to the relatively low values of the steady state C<sub>PP,2</sub>* in the absence of the inhibitor.</p>
</caption>
<graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1005216.g005" xlink:type="simple"/>
</fig>
<p>The presence of hormetic responses to an inhibitor which are masked at a population level could, therefore, complicate the interpretation of, and understanding gained from, preclinical models. Such complex sub-population effects have been noted for example in the NF-κB pathway, controlling DNA transcription, cytokine production and cell survival [<xref ref-type="bibr" rid="pcbi.1005216.ref071">71</xref>]. In particular, studies have shown that observing non-synchronous cells at a population level may under-represent oscillatory behaviour of nuclear shuttling [<xref ref-type="bibr" rid="pcbi.1005216.ref040">40</xref>, <xref ref-type="bibr" rid="pcbi.1005216.ref072">72</xref>–<xref ref-type="bibr" rid="pcbi.1005216.ref074">74</xref>].</p>
<p>Examining hormetic responses at single-cell level could substantially improve detection rates as well as help identify mechanisms driving hormesis. However, while measuring and analysing single-cell bacterial dose response to antibiotics is already feasible [<xref ref-type="bibr" rid="pcbi.1005216.ref075">75</xref>], such methodology has rarely been implemented for studying dose-responses of tumour cells. Therefore, a wider application of single-cell dose-response techniques used for prokaryotes to tumour cells will greatly enhance our understanding of hormesis in cancer settings.</p>
<p>The conclusions of our study are based on the assumption that the dual phosphorylation-dephosphorylation motif presented in <xref ref-type="disp-formula" rid="pcbi.1005216.e001">Eq (1)</xref> follows a distributive mechanism, whereby kinase (phosphatase) facilitates at most one phosphorylation (dephosphorylation) in each molecular encounter. This is motivated by the experimental evidence for MAPK pathways [<xref ref-type="bibr" rid="pcbi.1005216.ref051">51</xref>–<xref ref-type="bibr" rid="pcbi.1005216.ref053">53</xref>]. However, phosphorylation and dephosphorylation cycles can also follow a processive mechanism in which the kinase (phosphatase) facilitates two or more phosphorylations (dephosphorylations) before the final product is released [<xref ref-type="bibr" rid="pcbi.1005216.ref048">48</xref>]. In addition, a quasi-processive mechanism has been recently proposed to operate under the physiological condition of molecular crowding, which is a critical factor converting distributive into processive phosphorylation [<xref ref-type="bibr" rid="pcbi.1005216.ref076">76</xref>–<xref ref-type="bibr" rid="pcbi.1005216.ref078">78</xref>]. Our model can readily be extended to consider these alternative scenarios.</p>
<p>The findings presented here are relevant to applications in drug discovery relating to MAPK inhibition. Whereas inhibitors are specifically designed to target and suppress various stages in the MAPK pathways, the hormesis phenomenon leads to the opposite effect lowering the effectiveness of the compound and potentially leading to failure in the clinic [<xref ref-type="bibr" rid="pcbi.1005216.ref008">8</xref>, <xref ref-type="bibr" rid="pcbi.1005216.ref009">9</xref>, <xref ref-type="bibr" rid="pcbi.1005216.ref032">32</xref>]. Therefore, understanding mechanisms that lead to this undesired effect is important for designing inhibitors that would avoid them. Indeed, a recent study proposed a novel inhibitor, designed specifically to avoid MAPK activation at low-doses [<xref ref-type="bibr" rid="pcbi.1005216.ref079">79</xref>].</p>
<p>Our study could help achieve a similar goal. In particular, a straight forward approach to mitigate the risk of hormetic response is to favour inhibitor mechanisms of action for which this is impossible under our model. Protein substrate competitive inhibitors is one such example as these would generally, through steric hindrance, prohibit the formation of the necessary tertiary complex. In practice, structural biology can be employed to confirm that substrate and inhibitor complexes are mutually exclusive.</p>
<p>Overall, we argue that mathematical models are particularly useful tools in the drug-discovery process. Given the difficulties associated with measuring hormetic responses empirically be it with reductionist <italic>in vitro</italic> biochemical assays or cell based systems, the involvement of mathematical models in this process is of paramount importance. What we demonstrate here is that theoretical models classically make assumptions that immediately discount the possibility of observing hormetic responses in cell signalling pathways in the presence of inhibitors. Namely the assumption of no flux through substrate-kinase-inhibitor complex in motif <xref ref-type="disp-formula" rid="pcbi.1005216.e002">Eq (2)</xref> is widespread in theoretical literature despite the lack of empirical support. It is, therefore, crucial that model assumptions are regularly challenged so that important behaviours are not overlooked.</p>
</sec>
<sec id="sec006">
<title>Supporting Information</title>
<supplementary-material id="pcbi.1005216.s001" mimetype="application/pdf" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1005216.s001" xlink:type="simple">
<label>S1 Appendix</label>
<caption>
<title>The file contains a detailed mathematical model describing the time evolution of the substrate, kinase, phosphate and inhibitor concentrations, alongside the corresponding analysis and model parametrisation.</title>
<p>(PDF)</p>
</caption>
</supplementary-material>
</sec>
</body>
<back>
<ref-list>
<title>References</title>
<ref id="pcbi.1005216.ref001">
<label>1</label>
<mixed-citation publication-type="journal" xlink:type="simple">
<name name-style="western"><surname>Calabrese</surname> <given-names>EJ</given-names></name>, <name name-style="western"><surname>Baldwin</surname> <given-names>LA</given-names></name>. <article-title>Chemotherapeutics and hormesis</article-title>. <source>Crit Rev Toxicol</source>. <year>2003</year>;<volume>33</volume>(<issue>3–4</issue>):<fpage>305</fpage>–<lpage>353</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1080/713611041" xlink:type="simple">10.1080/713611041</ext-link></comment> <object-id pub-id-type="pmid">12809428</object-id></mixed-citation>
</ref>
<ref id="pcbi.1005216.ref002">
<label>2</label>
<mixed-citation publication-type="journal" xlink:type="simple">
<name name-style="western"><surname>Calabrese</surname> <given-names>EJ</given-names></name>. <article-title>Hormesis: a revolution in toxicology, risk assessment and medicine</article-title>. <source>EMBO Rep</source>. <year>2004</year>;<volume>5</volume>(<issue>Special Issue</issue>):<fpage>S37</fpage>–<lpage>S40</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/sj.embor.7400222" xlink:type="simple">10.1038/sj.embor.7400222</ext-link></comment> <object-id pub-id-type="pmid">15459733</object-id></mixed-citation>
</ref>
<ref id="pcbi.1005216.ref003">
<label>3</label>
<mixed-citation publication-type="journal" xlink:type="simple">
<name name-style="western"><surname>Raulin</surname> <given-names>J</given-names></name>. <article-title>Étudies chimiques sur la végétation</article-title>. <source>Ann Sci Nat Paris, sér 5</source>. <year>1869</year>;<volume>11</volume>:<fpage>93</fpage>–<lpage>299</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1005216.ref004">
<label>4</label>
<mixed-citation publication-type="journal" xlink:type="simple">
<name name-style="western"><surname>Schulz</surname> <given-names>H</given-names></name>. <article-title>Über Hefegifte</article-title>. <source>Pflügers Arch Gesamte Physiol Menschen Tiere</source>. <year>1888</year>;<volume>42</volume>(<issue>1</issue>):<fpage>517</fpage>–<lpage>541</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1007/BF01669373" xlink:type="simple">10.1007/BF01669373</ext-link></comment></mixed-citation>
</ref>
<ref id="pcbi.1005216.ref005">
<label>5</label>
<mixed-citation publication-type="journal" xlink:type="simple">
<name name-style="western"><surname>Hotchkiss</surname> <given-names>M</given-names></name>. <article-title>Studies on salt action VI. The stimulating and inhibitive effect of certain cations upon bacterial growth</article-title>. <source>J Bacteriol</source>. <year>1923</year>;<volume>8</volume>:<fpage>141</fpage>–<lpage>162</lpage>. <object-id pub-id-type="pmid">16558991</object-id></mixed-citation>
</ref>
<ref id="pcbi.1005216.ref006">
<label>6</label>
<mixed-citation publication-type="journal" xlink:type="simple">
<name name-style="western"><surname>Davies</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Spiegelman</surname> <given-names>GB</given-names></name>, <name name-style="western"><surname>Yim</surname> <given-names>G</given-names></name>. <article-title>The world of subinhibitory antibiotic concentrations</article-title>. <source>Curr Opin Microbiol</source>. <year>2006</year>;<volume>9</volume>(<issue>5</issue>):<fpage>445</fpage>–<lpage>453</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.mib.2006.08.006" xlink:type="simple">10.1016/j.mib.2006.08.006</ext-link></comment> <object-id pub-id-type="pmid">16942902</object-id></mixed-citation>
</ref>
<ref id="pcbi.1005216.ref007">
<label>7</label>
<mixed-citation publication-type="journal" xlink:type="simple">
<name name-style="western"><surname>Calabrese</surname> <given-names>EJ</given-names></name>. <article-title>Hormetic mechanisms</article-title>. <source>Crit Rev Toxicol</source>. <year>2013</year>;<volume>43</volume>(<issue>7</issue>):<fpage>580</fpage>–<lpage>606</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.3109/10408444.2013.808172" xlink:type="simple">10.3109/10408444.2013.808172</ext-link></comment> <object-id pub-id-type="pmid">23875765</object-id></mixed-citation>
</ref>
<ref id="pcbi.1005216.ref008">
<label>8</label>
<mixed-citation publication-type="journal" xlink:type="simple">
<name name-style="western"><surname>Callahan</surname> <given-names>MK</given-names></name>, <name name-style="western"><surname>Rampal</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Harding</surname> <given-names>JJ</given-names></name>, <name name-style="western"><surname>Klimek</surname> <given-names>VM</given-names></name>, <name name-style="western"><surname>Chung</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Merghoub</surname> <given-names>T</given-names></name>, <etal>et al</etal>. <article-title>Progression of RAS-mutant leukemia during RAF inhibitor treatment</article-title>. <source>N Engl J Med</source>. <year>2012</year>;<volume>367</volume>(<issue>24</issue>):<fpage>2316</fpage>–<lpage>2321</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1056/NEJMoa1208958" xlink:type="simple">10.1056/NEJMoa1208958</ext-link></comment> <object-id pub-id-type="pmid">23134356</object-id></mixed-citation>
</ref>
<ref id="pcbi.1005216.ref009">
<label>9</label>
<mixed-citation publication-type="journal" xlink:type="simple">
<name name-style="western"><surname>Su</surname> <given-names>F</given-names></name>, <name name-style="western"><surname>Viros</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Milagre</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Trunzer</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Bollah</surname> <given-names>G</given-names></name>, <name name-style="western"><surname>Spleiss</surname> <given-names>O</given-names></name>, <etal>et al</etal>. <article-title>RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors</article-title>. <source>N Engl J Med</source>. <year>2012</year>;<volume>366</volume>(<issue>3</issue>):<fpage>207</fpage>–<lpage>215</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1056/NEJMoa1105358" xlink:type="simple">10.1056/NEJMoa1105358</ext-link></comment> <object-id pub-id-type="pmid">22256804</object-id></mixed-citation>
</ref>
<ref id="pcbi.1005216.ref010">
<label>10</label>
<mixed-citation publication-type="journal" xlink:type="simple">
<name name-style="western"><surname>Imming</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Sinning</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Meyer</surname> <given-names>A</given-names></name>. <article-title>Drugs, their targets and the nature and number of drug targets</article-title>. <source>Nat Rev Drug Discov</source>. <year>2006</year>;<volume>5</volume>:<fpage>821</fpage>–<lpage>834</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/nrd2132" xlink:type="simple">10.1038/nrd2132</ext-link></comment> <object-id pub-id-type="pmid">17016423</object-id></mixed-citation>
</ref>
<ref id="pcbi.1005216.ref011">
<label>11</label>
<mixed-citation publication-type="book" xlink:type="simple">
<name name-style="western"><surname>Garzon</surname> <given-names>CD</given-names></name>, <name name-style="western"><surname>Flores</surname> <given-names>FJ</given-names></name>. <chapter-title>Hormesis: biphasic dose-responses to fungicides in plant pathogens and their potential threat to agriculture</chapter-title>. In: <name name-style="western"><surname>Nita</surname> <given-names>M</given-names></name>, editor. <source>Fungicides—showcases of integrated plant disease management from around the world</source>. <publisher-name>InTech</publisher-name>; <year>2013</year>. pp. <fpage>311</fpage>–<lpage>328</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1005216.ref012">
<label>12</label>
<mixed-citation publication-type="journal" xlink:type="simple">
<name name-style="western"><surname>Calabrese</surname> <given-names>EJ</given-names></name>, <name name-style="western"><surname>Baldwin</surname> <given-names>LA</given-names></name>. <article-title>Hormesis: a generalizable and unifying hypothesis</article-title>. <source>Crit Rev Toxicol</source>. <year>2001</year>;<volume>31</volume>(<issue>4–5</issue>):<fpage>353</fpage>–<lpage>424</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1080/20014091111730" xlink:type="simple">10.1080/20014091111730</ext-link></comment> <object-id pub-id-type="pmid">11504172</object-id></mixed-citation>
</ref>
<ref id="pcbi.1005216.ref013">
<label>13</label>
<mixed-citation publication-type="journal" xlink:type="simple">
<name name-style="western"><surname>Conolly</surname> <given-names>RB</given-names></name>, <name name-style="western"><surname>Lutz</surname> <given-names>WK</given-names></name>. <article-title>Nonmonotonic dose-response relationships: mechanistic basis, kinetic modeling, and implications for risk assessment</article-title>. <source>Toxicol Sci</source>. <year>2004</year>;<volume>77</volume>(<issue>1</issue>):<fpage>151</fpage>–<lpage>157</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1093/toxsci/kfh007" xlink:type="simple">10.1093/toxsci/kfh007</ext-link></comment> <object-id pub-id-type="pmid">14600281</object-id></mixed-citation>
</ref>
<ref id="pcbi.1005216.ref014">
<label>14</label>
<mixed-citation publication-type="journal" xlink:type="simple">
<name name-style="western"><surname>Bae</surname> <given-names>ON</given-names></name>, <name name-style="western"><surname>Lim</surname> <given-names>KM</given-names></name>, <name name-style="western"><surname>Han</surname> <given-names>JY</given-names></name>, <name name-style="western"><surname>Jung</surname> <given-names>BI</given-names></name>, <name name-style="western"><surname>Lee</surname> <given-names>JY</given-names></name>, <name name-style="western"><surname>Noh</surname> <given-names>JY</given-names></name>, <etal>et al</etal>. <article-title>U-shaped dose response in vasomotor tone: A mixed result of heterogenic response of multiple cells to xenobiotics</article-title>. <source>Toxicol Sci</source>. <year>2008</year>;<volume>103</volume>(<issue>1</issue>):<fpage>181</fpage>–<lpage>190</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1093/toxsci/kfn023" xlink:type="simple">10.1093/toxsci/kfn023</ext-link></comment> <object-id pub-id-type="pmid">18281258</object-id></mixed-citation>
</ref>
<ref id="pcbi.1005216.ref015">
<label>15</label>
<mixed-citation publication-type="journal" xlink:type="simple">
<name name-style="western"><surname>Szabadi</surname> <given-names>E</given-names></name>. <article-title>A model of two functionally antagonistic receptor populations activated by the same agonist</article-title>. <source>J Theor Biol</source>. <year>1977</year>;<volume>69</volume>(<issue>1</issue>):<fpage>101</fpage>–<lpage>112</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/0022-5193(77)90390-3" xlink:type="simple">10.1016/0022-5193(77)90390-3</ext-link></comment> <object-id pub-id-type="pmid">592862</object-id></mixed-citation>
</ref>
<ref id="pcbi.1005216.ref016">
<label>16</label>
<mixed-citation publication-type="journal" xlink:type="simple">
<name name-style="western"><surname>Nicolaou</surname> <given-names>KC</given-names></name>, <name name-style="western"><surname>Boddy</surname> <given-names>CNC</given-names></name>, <name name-style="western"><surname>Bräse</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Winssinger</surname> <given-names>N</given-names></name>. <article-title>Chemistry, biology, and medicine of the glycopeptide antibiotics</article-title>. <source>Angew Chem Int Ed Engl</source>. <year>1999</year>;<volume>38</volume>(<issue>15</issue>):<fpage>2096</fpage>–<lpage>2152</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1002/(SICI)1521-3773(19990802)38:15%3C2096::AID-ANIE2096%3E3.0.CO;2-F" xlink:type="simple">10.1002/(SICI)1521-3773(19990802)38:15%3C2096::AID-ANIE2096%3E3.0.CO;2-F</ext-link></comment> <object-id pub-id-type="pmid">10425471</object-id></mixed-citation>
</ref>
<ref id="pcbi.1005216.ref017">
<label>17</label>
<mixed-citation publication-type="journal" xlink:type="simple">
<name name-style="western"><surname>Maertens</surname> <given-names>Ja</given-names></name>. <article-title>History of the development of azole derivatives</article-title>. <source>Clin Microbiology Infect</source>. <year>2004</year>;<volume>10</volume> <issue>Suppl 1</issue>:<fpage>1</fpage>–<lpage>10</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1111/j.1470-9465.2004.00841.x" xlink:type="simple">10.1111/j.1470-9465.2004.00841.x</ext-link></comment> <object-id pub-id-type="pmid">14748798</object-id></mixed-citation>
</ref>
<ref id="pcbi.1005216.ref018">
<label>18</label>
<mixed-citation publication-type="journal" xlink:type="simple">
<name name-style="western"><surname>Denning</surname> <given-names>DW</given-names></name>. <article-title>Echinocandin antifungal drugs</article-title>. <source>The Lancet</source>. <year>2003</year>;<volume>362</volume>(<issue>9390</issue>):<fpage>1142</fpage>–<lpage>1151</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/S0140-6736(03)14472-8" xlink:type="simple">10.1016/S0140-6736(03)14472-8</ext-link></comment> <object-id pub-id-type="pmid">14550704</object-id></mixed-citation>
</ref>
<ref id="pcbi.1005216.ref019">
<label>19</label>
<mixed-citation publication-type="journal" xlink:type="simple">
<name name-style="western"><surname>Nitiss</surname> <given-names>J</given-names></name>. <article-title>Targeting DNA topoisomerase II in cancer chemotherapy</article-title>. <source>Nat Rev Cancer</source>. <year>2009</year>;<volume>9</volume>(<issue>5</issue>):<fpage>338</fpage>–<lpage>350</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/nrc2607" xlink:type="simple">10.1038/nrc2607</ext-link></comment> <object-id pub-id-type="pmid">19377506</object-id></mixed-citation>
</ref>
<ref id="pcbi.1005216.ref020">
<label>20</label>
<mixed-citation publication-type="journal" xlink:type="simple">
<name name-style="western"><surname>Deng</surname> <given-names>Z</given-names></name>, <name name-style="western"><surname>Lin</surname> <given-names>Z</given-names></name>, <name name-style="western"><surname>Zou</surname> <given-names>X</given-names></name>, <name name-style="western"><surname>Yao</surname> <given-names>Z</given-names></name>, <name name-style="western"><surname>Tian</surname> <given-names>D</given-names></name>, <name name-style="western"><surname>Wang</surname> <given-names>D</given-names></name>, <etal>et al</etal>. <article-title>Model of hormesis and its toxicity mechanism based on quorum sensing: A case study on the toxicity of sulfonamides to Photobacterium phosphoreum</article-title>. <source>Environ Sci Technol</source>. <year>2012</year>;<volume>46</volume>(<issue>14</issue>):<fpage>7746</fpage>–<lpage>7754</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1021/es203490f" xlink:type="simple">10.1021/es203490f</ext-link></comment> <object-id pub-id-type="pmid">22715968</object-id></mixed-citation>
</ref>
<ref id="pcbi.1005216.ref021">
<label>21</label>
<mixed-citation publication-type="journal" xlink:type="simple">
<name name-style="western"><surname>Chapman</surname> <given-names>PB</given-names></name>, <name name-style="western"><surname>Hauschild</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Robert</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Haanen</surname> <given-names>JB</given-names></name>, <name name-style="western"><surname>Ascierto</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Larkin</surname> <given-names>J</given-names></name>, <etal>et al</etal>. <article-title>Improved survival with vemurafenib in melanoma with BRAF V600E mutation</article-title>. <source>N Engl J Med</source>. <year>2011</year>;<volume>364</volume>(<issue>26</issue>):<fpage>2507</fpage>–<lpage>2516</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1056/NEJMoa1103782" xlink:type="simple">10.1056/NEJMoa1103782</ext-link></comment> <object-id pub-id-type="pmid">21639808</object-id></mixed-citation>
</ref>
<ref id="pcbi.1005216.ref022">
<label>22</label>
<mixed-citation publication-type="journal" xlink:type="simple">
<name name-style="western"><surname>Sosman</surname> <given-names>JA</given-names></name>, <name name-style="western"><surname>Kim</surname> <given-names>KB</given-names></name>, <name name-style="western"><surname>Schuchter</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>Gonzalez</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Pavlick</surname> <given-names>AC</given-names></name>, <name name-style="western"><surname>Weber</surname> <given-names>JS</given-names></name>, <etal>et al</etal>. <article-title>Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib</article-title>. <source>N Engl J Med</source>. <year>2012</year>;<volume>366</volume>(<issue>8</issue>):<fpage>707</fpage>–<lpage>714</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1056/NEJMoa1112302" xlink:type="simple">10.1056/NEJMoa1112302</ext-link></comment> <object-id pub-id-type="pmid">22356324</object-id></mixed-citation>
</ref>
<ref id="pcbi.1005216.ref023">
<label>23</label>
<mixed-citation publication-type="journal" xlink:type="simple">
<name name-style="western"><surname>Hauschild</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Grob</surname> <given-names>JJ</given-names></name>, <name name-style="western"><surname>Demidov</surname> <given-names>LV</given-names></name>, <name name-style="western"><surname>Jouary</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Gutzmer</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Millward</surname> <given-names>M</given-names></name>, <etal>et al</etal>. <article-title>Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial</article-title>. <source>The Lancet</source>. <year>2012</year>;<volume>380</volume>(<issue>9839</issue>):<fpage>358</fpage>–<lpage>365</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/S0140-6736(12)60868-X" xlink:type="simple">10.1016/S0140-6736(12)60868-X</ext-link></comment> <object-id pub-id-type="pmid">22735384</object-id></mixed-citation>
</ref>
<ref id="pcbi.1005216.ref024">
<label>24</label>
<mixed-citation publication-type="journal" xlink:type="simple">
<name name-style="western"><surname>Flaherty</surname> <given-names>KT</given-names></name>, <name name-style="western"><surname>Puzanov</surname> <given-names>I</given-names></name>, <name name-style="western"><surname>Kim</surname> <given-names>KB</given-names></name>, <name name-style="western"><surname>Ribas</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>McArthur</surname> <given-names>GA</given-names></name>, <name name-style="western"><surname>Sosman</surname> <given-names>JA</given-names></name>, <etal>et al</etal>. <article-title>Inhibition of mutated, activated BRAF in metastatic melanoma</article-title>. <source>N Engl J Med</source>. <year>2010</year>;<volume>363</volume>(<issue>9</issue>):<fpage>809</fpage>–<lpage>819</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1056/NEJMoa1002011" xlink:type="simple">10.1056/NEJMoa1002011</ext-link></comment> <object-id pub-id-type="pmid">20818844</object-id></mixed-citation>
</ref>
<ref id="pcbi.1005216.ref025">
<label>25</label>
<mixed-citation publication-type="journal" xlink:type="simple">
<name name-style="western"><surname>Roberts</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Der</surname> <given-names>C</given-names></name>. <article-title>Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer</article-title>. <source>Oncogene</source>. <year>2007</year>;<volume>26</volume>:<fpage>3291</fpage>–<lpage>3310</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/sj.onc.1210422" xlink:type="simple">10.1038/sj.onc.1210422</ext-link></comment> <object-id pub-id-type="pmid">17496923</object-id></mixed-citation>
</ref>
<ref id="pcbi.1005216.ref026">
<label>26</label>
<mixed-citation publication-type="journal" xlink:type="simple">
<name name-style="western"><surname>Davies</surname> <given-names>H</given-names></name>, <name name-style="western"><surname>Bignell</surname> <given-names>GR</given-names></name>, <name name-style="western"><surname>Cox</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Stephens</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Edkins</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Clegg</surname> <given-names>S</given-names></name>, <etal>et al</etal>. <article-title>Mutations of the BRAF gene in human cancer</article-title>. <source>Nature</source>. <year>2002</year>;<volume>417</volume>(<issue>6892</issue>):<fpage>949</fpage>–<lpage>954</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/nature00766" xlink:type="simple">10.1038/nature00766</ext-link></comment> <object-id pub-id-type="pmid">12068308</object-id></mixed-citation>
</ref>
<ref id="pcbi.1005216.ref027">
<label>27</label>
<mixed-citation publication-type="journal" xlink:type="simple">
<name name-style="western"><surname>Hall-Jackson</surname> <given-names>CA</given-names></name>, <name name-style="western"><surname>Eyers</surname> <given-names>PA</given-names></name>, <name name-style="western"><surname>Cohen</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Goedert</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Boyle</surname> <given-names>FT</given-names></name>, <name name-style="western"><surname>Hewitt</surname> <given-names>N</given-names></name>, <etal>et al</etal>. <article-title>Paradoxical activation of RAF by a novel RAF inhibitor</article-title>. <source>Chem Biol</source>. <year>1999</year>;<volume>6</volume>(<issue>8</issue>):<fpage>559</fpage>–<lpage>568</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/S1074-5521(99)80088-X" xlink:type="simple">10.1016/S1074-5521(99)80088-X</ext-link></comment> <object-id pub-id-type="pmid">10421767</object-id></mixed-citation>
</ref>
<ref id="pcbi.1005216.ref028">
<label>28</label>
<mixed-citation publication-type="journal" xlink:type="simple">
<name name-style="western"><surname>Poulikakos</surname> <given-names>PI</given-names></name>, <name name-style="western"><surname>Zhang</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Bollag</surname> <given-names>G</given-names></name>, <name name-style="western"><surname>Shokat</surname> <given-names>KM</given-names></name>, <name name-style="western"><surname>Rosen</surname> <given-names>N</given-names></name>. <article-title>RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF</article-title>. <source>Nature</source>. <year>2010</year>;<volume>464</volume>(<issue>7287</issue>):<fpage>427</fpage>–<lpage>30</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/nature08902" xlink:type="simple">10.1038/nature08902</ext-link></comment> <object-id pub-id-type="pmid">20179705</object-id></mixed-citation>
</ref>
<ref id="pcbi.1005216.ref029">
<label>29</label>
<mixed-citation publication-type="journal" xlink:type="simple">
<name name-style="western"><surname>Heidorn</surname> <given-names>SJ</given-names></name>, <name name-style="western"><surname>Milagre</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Whittaker</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Nourry</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Niculescu-Duvas</surname> <given-names>I</given-names></name>, <name name-style="western"><surname>Dhomen</surname> <given-names>N</given-names></name>, <etal>et al</etal>. <article-title>Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF</article-title>. <source>Cell</source>. <year>2010</year>;<volume>140</volume>(<issue>2</issue>):<fpage>209</fpage>–<lpage>221</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.cell.2009.12.040" xlink:type="simple">10.1016/j.cell.2009.12.040</ext-link></comment> <object-id pub-id-type="pmid">20141835</object-id></mixed-citation>
</ref>
<ref id="pcbi.1005216.ref030">
<label>30</label>
<mixed-citation publication-type="journal" xlink:type="simple">
<name name-style="western"><surname>Hatzivassiliou</surname> <given-names>G</given-names></name>, <name name-style="western"><surname>Song</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Yen</surname> <given-names>I</given-names></name>, <name name-style="western"><surname>Brandhuber</surname> <given-names>BJ</given-names></name>, <name name-style="western"><surname>Anderson</surname> <given-names>DJ</given-names></name>, <name name-style="western"><surname>Alvarado</surname> <given-names>R</given-names></name>, <etal>et al</etal>. <article-title>RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth</article-title>. <source>Nature</source>. <year>2010</year>;<volume>464</volume>(<issue>7287</issue>):<fpage>431</fpage>–<lpage>435</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/nature08833" xlink:type="simple">10.1038/nature08833</ext-link></comment> <object-id pub-id-type="pmid">20130576</object-id></mixed-citation>
</ref>
<ref id="pcbi.1005216.ref031">
<label>31</label>
<mixed-citation publication-type="journal" xlink:type="simple">
<name name-style="western"><surname>Andrews</surname> <given-names>MC</given-names></name>, <name name-style="western"><surname>Behren</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Chionh</surname> <given-names>F</given-names></name>, <name name-style="western"><surname>Mariadason</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Vella</surname> <given-names>LJ</given-names></name>, <name name-style="western"><surname>Do</surname> <given-names>H</given-names></name>, <etal>et al</etal>. <article-title>BRAF inhibitor-driven tumor proliferation in a KRAS-mutated colon carcinoma is not overcome by MEK1/2 inhibition</article-title>. <source>J Clin Oncol</source>. <year>2010</year>;<volume>31</volume>(<issue>35</issue>):<fpage>e448</fpage>–<lpage>e451</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1200/JCO.2013.50.4118" xlink:type="simple">10.1200/JCO.2013.50.4118</ext-link></comment> <object-id pub-id-type="pmid">24190114</object-id></mixed-citation>
</ref>
<ref id="pcbi.1005216.ref032">
<label>32</label>
<mixed-citation publication-type="journal" xlink:type="simple">
<name name-style="western"><surname>Zimmer</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>Hillen</surname> <given-names>U</given-names></name>, <name name-style="western"><surname>Livingstone</surname> <given-names>E</given-names></name>, <name name-style="western"><surname>Lacouture</surname> <given-names>ME</given-names></name>, <name name-style="western"><surname>Busam</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Carvajal</surname> <given-names>RD</given-names></name>, <etal>et al</etal>. <article-title>Atypical melanocytic proliferations and new primary melanomas in patients with advanced melanoma undergoing selective BRAF Inhibition</article-title>. <source>J Clin Oncol</source>. <year>2012</year>;<volume>30</volume>(<issue>19</issue>):<fpage>2375</fpage>–<lpage>2383</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1200/JCO.2011.41.1660" xlink:type="simple">10.1200/JCO.2011.41.1660</ext-link></comment> <object-id pub-id-type="pmid">22614973</object-id></mixed-citation>
</ref>
<ref id="pcbi.1005216.ref033">
<label>33</label>
<mixed-citation publication-type="journal" xlink:type="simple">
<name name-style="western"><surname>Holderfield</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Nagel</surname> <given-names>TE</given-names></name>, <name name-style="western"><surname>Stuart</surname> <given-names>DD</given-names></name>. <article-title>Mechanism and consequences of RAF kinase activation by small-molecule inhibitors</article-title>. <source>Br J Cancer</source>. <year>2014</year>;<volume>111</volume>(<issue>4</issue>):<fpage>640</fpage>–<lpage>645</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/bjc.2014.139" xlink:type="simple">10.1038/bjc.2014.139</ext-link></comment> <object-id pub-id-type="pmid">24642617</object-id></mixed-citation>
</ref>
<ref id="pcbi.1005216.ref034">
<label>34</label>
<mixed-citation publication-type="journal" xlink:type="simple">
<name name-style="western"><surname>Ortega</surname> <given-names>F</given-names></name>, <name name-style="western"><surname>Stott</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Visser</surname> <given-names>SAG</given-names></name>, <name name-style="western"><surname>Bendtsen</surname> <given-names>C</given-names></name>. <article-title>Interplay between <italic>α</italic>-, <italic>β</italic>-, and <italic>γ</italic>-secretases determines biphasic amyloid-<italic>β</italic> protein level in the presence of a <italic>γ</italic>-secretase inhibitor</article-title>. <source>J Biol Chem</source>. <year>2013</year>;<volume>288</volume>(<issue>2</issue>):<fpage>785</fpage>–<lpage>792</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1074/jbc.M112.419135" xlink:type="simple">10.1074/jbc.M112.419135</ext-link></comment> <object-id pub-id-type="pmid">23152503</object-id></mixed-citation>
</ref>
<ref id="pcbi.1005216.ref035">
<label>35</label>
<mixed-citation publication-type="journal" xlink:type="simple">
<name name-style="western"><surname>Nishiwaki</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Satomi</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Kitayama</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Terauchi</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Kiyohara</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Takao</surname> <given-names>T</given-names></name>, <etal>et al</etal>. <article-title>A sequential program of dual phosphorylation of KaiC as a basis for circadian rhythm in cyanobacteria</article-title>. <source>EMBO J</source>. <year>2007</year>;<volume>26</volume>(<issue>17</issue>):<fpage>4029</fpage>–<lpage>4037</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/sj.emboj.7601832" xlink:type="simple">10.1038/sj.emboj.7601832</ext-link></comment> <object-id pub-id-type="pmid">17717528</object-id></mixed-citation>
</ref>
<ref id="pcbi.1005216.ref036">
<label>36</label>
<mixed-citation publication-type="journal" xlink:type="simple">
<name name-style="western"><surname>Horstmann</surname> <given-names>N</given-names></name>, <name name-style="western"><surname>Saldana</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Sahasrabhojane</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Yao</surname> <given-names>H</given-names></name>, <name name-style="western"><surname>Su</surname> <given-names>X</given-names></name>, <name name-style="western"><surname>Thompson</surname> <given-names>E</given-names></name>, <etal>et al</etal>. <article-title>Dual-site phosphorylation of the control of virulence regulator impacts group A streptococcal global gene expression and pathogenesis</article-title>. <source>PLoS Pathog</source>. <year>2014</year>;<volume>10</volume>(<issue>5</issue>):<fpage>e1004088</fpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1371/journal.ppat.1004088" xlink:type="simple">10.1371/journal.ppat.1004088</ext-link></comment> <object-id pub-id-type="pmid">24788524</object-id></mixed-citation>
</ref>
<ref id="pcbi.1005216.ref037">
<label>37</label>
<mixed-citation publication-type="journal" xlink:type="simple">
<name name-style="western"><surname>Whitmore</surname> <given-names>SE</given-names></name>, <name name-style="western"><surname>Lamont</surname> <given-names>RJ</given-names></name>. <article-title>Tyrosine phosphorylation and bacterial virulence</article-title>. <source>Int J Oral Sci</source>. <year>2012</year>;<volume>4</volume>(<issue>1</issue>):<fpage>1</fpage>–<lpage>6</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/ijos.2012.6" xlink:type="simple">10.1038/ijos.2012.6</ext-link></comment> <object-id pub-id-type="pmid">22388693</object-id></mixed-citation>
</ref>
<ref id="pcbi.1005216.ref038">
<label>38</label>
<mixed-citation publication-type="journal" xlink:type="simple">
<name name-style="western"><surname>Bulavin</surname> <given-names>DV</given-names></name>, <name name-style="western"><surname>Higashimoto</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Demidenko</surname> <given-names>ZN</given-names></name>, <name name-style="western"><surname>Meek</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Graves</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Phillips</surname> <given-names>C</given-names></name>, <etal>et al</etal>. <article-title>Dual phosphorylation controls Cdc25 phosphatases and mitotic entry</article-title>. <source>Nat Cell Biol</source>. <year>2003</year>;<volume>5</volume>(<issue>6</issue>):<fpage>545</fpage>–<lpage>551</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/ncb994" xlink:type="simple">10.1038/ncb994</ext-link></comment> <object-id pub-id-type="pmid">12766774</object-id></mixed-citation>
</ref>
<ref id="pcbi.1005216.ref039">
<label>39</label>
<mixed-citation publication-type="journal" xlink:type="simple">
<name name-style="western"><surname>Martin-Verstraete</surname> <given-names>I</given-names></name>, <name name-style="western"><surname>Charrier</surname> <given-names>V</given-names></name>, <name name-style="western"><surname>Stülke</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Galinier</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Erni</surname> <given-names>B</given-names></name>, <name name-style="western"><surname>Rapoport</surname> <given-names>G</given-names></name>, <etal>et al</etal>. <article-title>Antagonistic effects of dual PTS-catalysed phosphorylation on the Bacillus subtilis transcriptional activator LevR</article-title>. <source>Mol Microbiol</source>. <year>1998</year>;<volume>28</volume>(<issue>2</issue>):<fpage>293</fpage>–<lpage>303</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1046/j.1365-2958.1998.00781.x" xlink:type="simple">10.1046/j.1365-2958.1998.00781.x</ext-link></comment> <object-id pub-id-type="pmid">9622354</object-id></mixed-citation>
</ref>
<ref id="pcbi.1005216.ref040">
<label>40</label>
<mixed-citation publication-type="journal" xlink:type="simple">
<name name-style="western"><surname>Hoffmann</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Levchenko</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Scott</surname> <given-names>ML</given-names></name>, <name name-style="western"><surname>Baltimore</surname> <given-names>D</given-names></name>. <article-title>The I<italic>κ</italic>B-NF-<italic>κ</italic>B signaling module: temporal control and selective gene activation</article-title>. <source>Science</source>. <year>2002</year>;<volume>298</volume>(<issue>5596</issue>):<fpage>1241</fpage>–<lpage>1245</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1126/science.1071914" xlink:type="simple">10.1126/science.1071914</ext-link></comment> <object-id pub-id-type="pmid">12424381</object-id></mixed-citation>
</ref>
<ref id="pcbi.1005216.ref041">
<label>41</label>
<mixed-citation publication-type="journal" xlink:type="simple">
<name name-style="western"><surname>Widmann</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Gibson</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Jarpe</surname> <given-names>MB</given-names></name>, <name name-style="western"><surname>Johnson</surname> <given-names>GL</given-names></name>. <article-title>Mitogen-activated protein kinase: conservation of a three-kinase module from yeast to human</article-title>. <source>Physiol Rev</source>. <year>1999</year>;<volume>79</volume>(<issue>1</issue>):<fpage>143</fpage>–<lpage>180</lpage>. <object-id pub-id-type="pmid">9922370</object-id></mixed-citation>
</ref>
<ref id="pcbi.1005216.ref042">
<label>42</label>
<mixed-citation publication-type="journal" xlink:type="simple">
<name name-style="western"><surname>Chang</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>Karin</surname> <given-names>M</given-names></name>. <article-title>Mammalian MAP kinase signalling cascades</article-title>. <source>Nature</source>. <year>2001</year>;<volume>410</volume>(<issue>6824</issue>):<fpage>37</fpage>–<lpage>40</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/35065000" xlink:type="simple">10.1038/35065000</ext-link></comment> <object-id pub-id-type="pmid">11242034</object-id></mixed-citation>
</ref>
<ref id="pcbi.1005216.ref043">
<label>43</label>
<mixed-citation publication-type="journal" xlink:type="simple">
<name name-style="western"><surname>Cargnello</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Roux</surname> <given-names>PP</given-names></name>. <article-title>Activation and function of the MAPKs and their substrates, the MAPK-activated protein kinases</article-title>. <source>Microbiol Mol Biol Rev</source>. <year>2011</year>;<volume>75</volume>(<issue>1</issue>):<fpage>50</fpage>–<lpage>83</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1128/MMBR.00031-10" xlink:type="simple">10.1128/MMBR.00031-10</ext-link></comment> <object-id pub-id-type="pmid">21372320</object-id></mixed-citation>
</ref>
<ref id="pcbi.1005216.ref044">
<label>44</label>
<mixed-citation publication-type="journal" xlink:type="simple">
<name name-style="western"><surname>Ayeni</surname> <given-names>JO</given-names></name>, <name name-style="western"><surname>Varadarajan</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Mukherjee</surname> <given-names>O</given-names></name>, <name name-style="western"><surname>Stuart</surname> <given-names>DT</given-names></name>, <name name-style="western"><surname>Sprenger</surname> <given-names>F</given-names></name>, <name name-style="western"><surname>Srayko</surname> <given-names>M</given-names></name>, <etal>et al</etal>. <article-title>Dual phosphorylation of Cdk1 coordinates cell proliferation with key developmental processes in Drosophila</article-title>. <source>Genetics</source>. <year>2014</year>;<volume>196</volume>(<issue>1</issue>):<fpage>197</fpage>–<lpage>210</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1534/genetics.113.156281" xlink:type="simple">10.1534/genetics.113.156281</ext-link></comment> <object-id pub-id-type="pmid">24214341</object-id></mixed-citation>
</ref>
<ref id="pcbi.1005216.ref045">
<label>45</label>
<mixed-citation publication-type="journal" xlink:type="simple">
<name name-style="western"><surname>Fu</surname> <given-names>Z</given-names></name>, <name name-style="western"><surname>Larson</surname> <given-names>KA</given-names></name>, <name name-style="western"><surname>Chitta</surname> <given-names>RK</given-names></name>, <name name-style="western"><surname>Parker</surname> <given-names>SA</given-names></name>, <name name-style="western"><surname>Turk</surname> <given-names>BE</given-names></name>, <name name-style="western"><surname>Lawrence</surname> <given-names>MW</given-names></name>, <etal>et al</etal>. <article-title>Identification of yin-yang regulators and a phosphorylation consensus for male germ cell-associated kinase (MAK)-related kinase</article-title>. <source>Mol Cellr Biol</source>. <year>2006</year>;<volume>26</volume>(<issue>22</issue>):<fpage>8639</fpage>–<lpage>8654</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1128/MCB.00816-06" xlink:type="simple">10.1128/MCB.00816-06</ext-link></comment> <object-id pub-id-type="pmid">16954377</object-id></mixed-citation>
</ref>
<ref id="pcbi.1005216.ref046">
<label>46</label>
<mixed-citation publication-type="journal" xlink:type="simple">
<name name-style="western"><surname>Kilisch</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Lytovchenko</surname> <given-names>O</given-names></name>, <name name-style="western"><surname>Arakel</surname> <given-names>EC</given-names></name>, <name name-style="western"><surname>Bertinetti</surname> <given-names>D</given-names></name>, <name name-style="western"><surname>Schwappach</surname> <given-names>B</given-names></name>. <article-title>A dual phosphorylation switch controls 14-3-3-dependent cell surface expression of TASK-1</article-title>. <source>J Cell Sci</source>. <year>2016</year>;<volume>129</volume>(<issue>4</issue>):<fpage>831</fpage>–<lpage>842</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1242/jcs.180182" xlink:type="simple">10.1242/jcs.180182</ext-link></comment> <object-id pub-id-type="pmid">26743085</object-id></mixed-citation>
</ref>
<ref id="pcbi.1005216.ref047">
<label>47</label>
<mixed-citation publication-type="journal" xlink:type="simple">
<name name-style="western"><surname>Samoilov</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Plyasunov</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Arkin</surname> <given-names>AP</given-names></name>. <article-title>Stochastic amplification and signaling in enzymatic futile cycles through noise-induced bistability with oscillations</article-title>. <source>Proc Nat Acad Sci USA</source>. <year>2005</year>;<volume>102</volume>(<issue>7</issue>):<fpage>2310</fpage>–<lpage>2315</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1073/pnas.0406841102" xlink:type="simple">10.1073/pnas.0406841102</ext-link></comment> <object-id pub-id-type="pmid">15701703</object-id></mixed-citation>
</ref>
<ref id="pcbi.1005216.ref048">
<label>48</label>
<mixed-citation publication-type="journal" xlink:type="simple">
<name name-style="western"><surname>Wang</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>Sontag</surname> <given-names>ED</given-names></name>. <article-title>On the number of steady states in a multiple futile cycle</article-title>. <source>J Math Biol</source>. <year>2008</year>;<volume>57</volume>(<issue>1</issue>):<fpage>29</fpage>–<lpage>52</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1007/s00285-007-0145-z" xlink:type="simple">10.1007/s00285-007-0145-z</ext-link></comment> <object-id pub-id-type="pmid">18008071</object-id></mixed-citation>
</ref>
<ref id="pcbi.1005216.ref049">
<label>49</label>
<mixed-citation publication-type="journal" xlink:type="simple">
<name name-style="western"><surname>Huang</surname> <given-names>CY</given-names></name>, <name name-style="western"><surname>Ferrell</surname> <given-names>JE</given-names></name>. <article-title>Ultrasensitivity in the mitogen-activated protein kinase cascade</article-title>. <source>Proc Nat Acad Sci USA</source>. <year>1996</year>;<volume>93</volume>(<issue>19</issue>):<fpage>10078</fpage>–<lpage>10083</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1073/pnas.93.19.10078" xlink:type="simple">10.1073/pnas.93.19.10078</ext-link></comment> <object-id pub-id-type="pmid">8816754</object-id></mixed-citation>
</ref>
<ref id="pcbi.1005216.ref050">
<label>50</label>
<mixed-citation publication-type="journal" xlink:type="simple">
<name name-style="western"><surname>Qiao</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>Nachbar</surname> <given-names>RB</given-names></name>, <name name-style="western"><surname>Kevrekidis</surname> <given-names>IG</given-names></name>, <name name-style="western"><surname>Shvartsman</surname> <given-names>SY</given-names></name>. <article-title>Bistability and oscillations in the Huang-Ferrell model of MAPK signaling</article-title>. <source>PLoS Comput Biol</source>. <year>2007</year>;<volume>3</volume>(<issue>9</issue>):<fpage>1819</fpage>–<lpage>1826</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1371/journal.pcbi.0030184" xlink:type="simple">10.1371/journal.pcbi.0030184</ext-link></comment> <object-id pub-id-type="pmid">17907797</object-id></mixed-citation>
</ref>
<ref id="pcbi.1005216.ref051">
<label>51</label>
<mixed-citation publication-type="journal" xlink:type="simple">
<name name-style="western"><surname>Ferrell</surname> <given-names>JE</given-names></name>, <name name-style="western"><surname>Bhatt</surname> <given-names>RR</given-names></name>. <article-title>Mechanistic studies of the dual phosphorylation of mitogen-activated protein kinase</article-title>. <source>J Biol Chem</source>. <year>1997</year>;<volume>272</volume>(<issue>30</issue>):<fpage>19008</fpage>–<lpage>19016</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1074/jbc.272.30.19008" xlink:type="simple">10.1074/jbc.272.30.19008</ext-link></comment> <object-id pub-id-type="pmid">9228083</object-id></mixed-citation>
</ref>
<ref id="pcbi.1005216.ref052">
<label>52</label>
<mixed-citation publication-type="journal" xlink:type="simple">
<name name-style="western"><surname>Burack</surname> <given-names>WR</given-names></name>, <name name-style="western"><surname>Sturgill</surname> <given-names>TW</given-names></name>. <article-title>The activating dual phosphorylation of MAPK by MEK is nonprocessive</article-title>. <source>Biochemistry</source>. <year>1997</year>;<volume>36</volume>(<issue>20</issue>):<fpage>5929</fpage>–<lpage>5933</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1021/bi970535d" xlink:type="simple">10.1021/bi970535d</ext-link></comment> <object-id pub-id-type="pmid">9166761</object-id></mixed-citation>
</ref>
<ref id="pcbi.1005216.ref053">
<label>53</label>
<mixed-citation publication-type="journal" xlink:type="simple">
<name name-style="western"><surname>Zhao</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Zhang</surname> <given-names>ZY</given-names></name>. <article-title>The mechanism of dephosphorylation of extracellular signal-regulated kinase 2 by mitogen-activated protein kinase phosphatase 3</article-title>. <source>J Biol Chem</source>. <year>2001</year>;<volume>276</volume>(<issue>34</issue>):<fpage>32382</fpage>–<lpage>32391</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1074/jbc.M103369200" xlink:type="simple">10.1074/jbc.M103369200</ext-link></comment> <object-id pub-id-type="pmid">11432864</object-id></mixed-citation>
</ref>
<ref id="pcbi.1005216.ref054">
<label>54</label>
<mixed-citation publication-type="journal" xlink:type="simple">
<name name-style="western"><surname>Markevich</surname> <given-names>NI</given-names></name>, <name name-style="western"><surname>Hoek</surname> <given-names>JB</given-names></name>, <name name-style="western"><surname>Kholodenko</surname> <given-names>BN</given-names></name>. <article-title>Signaling switches and bistability arising from multisite phosphorylation in protein kinase cascades</article-title>. <source>J Cell Biol</source>. <year>2004</year>;<volume>164</volume>(<issue>3</issue>):<fpage>353</fpage>–<lpage>359</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1083/jcb.200308060" xlink:type="simple">10.1083/jcb.200308060</ext-link></comment> <object-id pub-id-type="pmid">14744999</object-id></mixed-citation>
</ref>
<ref id="pcbi.1005216.ref055">
<label>55</label>
<mixed-citation publication-type="book" xlink:type="simple">
<name name-style="western"><surname>Cornish-Bowden</surname> <given-names>A</given-names></name>. <source>Fundamentals of enzyme kinetics</source>. <publisher-loc>London</publisher-loc>: <publisher-name>Portland Press</publisher-name>; <year>1995</year>.</mixed-citation>
</ref>
<ref id="pcbi.1005216.ref056">
<label>56</label>
<mixed-citation publication-type="book" xlink:type="simple">
<name name-style="western"><surname>Segel</surname> <given-names>I</given-names></name>. <source>Enzyme kinetics: behavior and analysis of rapid equilibrium and steady-state enzyme systems</source>. <publisher-name>Wiley</publisher-name>; <year>1993</year>.</mixed-citation>
</ref>
<ref id="pcbi.1005216.ref057">
<label>57</label>
<mixed-citation publication-type="journal" xlink:type="simple">
<name name-style="western"><surname>Dhooge</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Govaerts</surname> <given-names>W</given-names></name>, <name name-style="western"><surname>Kuznetsov</surname> <given-names>YA</given-names></name>. <article-title>MATCONT: A MATLAB package for numerical bifurcation analysis of ODEs</article-title>. <source>ACM Trans Math Software</source>. <year>2003</year>;<volume>29</volume>:<fpage>141</fpage>–<lpage>164</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1145/779359.779362" xlink:type="simple">10.1145/779359.779362</ext-link></comment></mixed-citation>
</ref>
<ref id="pcbi.1005216.ref058">
<label>58</label>
<mixed-citation publication-type="journal" xlink:type="simple">
<name name-style="western"><surname>Ortega</surname> <given-names>F</given-names></name>, <name name-style="western"><surname>Garcés</surname> <given-names>JL</given-names></name>, <name name-style="western"><surname>Mas</surname> <given-names>F</given-names></name>, <name name-style="western"><surname>Kholodenko</surname> <given-names>BN</given-names></name>, <name name-style="western"><surname>Cascante</surname> <given-names>M</given-names></name>. <article-title>Bistability from double phosphorylation in signal transduction: kinetic and structural requirements</article-title>. <source>FEBS J</source>. <year>2006</year>;<volume>273</volume>(<issue>17</issue>):<fpage>3915</fpage>–<lpage>3926</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1111/j.1742-4658.2006.05394.x" xlink:type="simple">10.1111/j.1742-4658.2006.05394.x</ext-link></comment> <object-id pub-id-type="pmid">16934033</object-id></mixed-citation>
</ref>
<ref id="pcbi.1005216.ref059">
<label>59</label>
<mixed-citation publication-type="journal" xlink:type="simple">
<name name-style="western"><surname>Conradi</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Mincheva</surname> <given-names>M</given-names></name>. <article-title>Catalytic constants enable the emergence of bistability in dual phosphorylation</article-title>. <source>J R Soc Interface</source>. <year>2014</year>;<volume>11</volume>(<issue>95</issue>):<fpage>20140158</fpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1098/rsif.2014.0158" xlink:type="simple">10.1098/rsif.2014.0158</ext-link></comment> <object-id pub-id-type="pmid">24647909</object-id></mixed-citation>
</ref>
<ref id="pcbi.1005216.ref060">
<label>60</label>
<mixed-citation publication-type="journal" xlink:type="simple">
<name name-style="western"><surname>Wang</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Weiss</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Simonovic</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Haertinger</surname> <given-names>G</given-names></name>, <name name-style="western"><surname>Schrimpf</surname> <given-names>SP</given-names></name>, <name name-style="western"><surname>Hengartner</surname> <given-names>MO</given-names></name>, <etal>et al</etal>. <article-title>PaxDb, a database of protein abundance averages across all three domains of life</article-title>. <source>Mol Cell Proteomics</source>. <year>2012</year>;<volume>11</volume>(<issue>8</issue>):<fpage>492</fpage>–<lpage>500</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1074/mcp.O111.014704" xlink:type="simple">10.1074/mcp.O111.014704</ext-link></comment> <object-id pub-id-type="pmid">22535208</object-id></mixed-citation>
</ref>
<ref id="pcbi.1005216.ref061">
<label>61</label>
<mixed-citation publication-type="journal" xlink:type="simple">
<name name-style="western"><surname>Yoh</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Frimpong</surname> <given-names>E</given-names></name>, <name name-style="western"><surname>Voravuthikunchai</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Honda</surname> <given-names>T</given-names></name>. <article-title>Effect of subinhibitory concentrations of antimicrobial agents (quinolones and macrolide) on the production of verotoxin by enterohemorrhagic Escherichia coli O157:H7</article-title>. <source>Can J Microbiol</source>. <year>1999</year>;<volume>45</volume>(<issue>9</issue>):<fpage>732</fpage>–<lpage>739</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1139/w99-069" xlink:type="simple">10.1139/w99-069</ext-link></comment> <object-id pub-id-type="pmid">10526400</object-id></mixed-citation>
</ref>
<ref id="pcbi.1005216.ref062">
<label>62</label>
<mixed-citation publication-type="journal" xlink:type="simple">
<name name-style="western"><surname>Seyedsayamdost</surname> <given-names>MR</given-names></name>. <article-title>High-throughput platform for the discovery of elicitors of silent bacterial gene clusters</article-title>. <source>Proc Nat Acad Sci USA</source>. <year>2014</year>;<volume>111</volume>(<issue>20</issue>):<fpage>7266</fpage>–<lpage>7271</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1073/pnas.1400019111" xlink:type="simple">10.1073/pnas.1400019111</ext-link></comment> <object-id pub-id-type="pmid">24808135</object-id></mixed-citation>
</ref>
<ref id="pcbi.1005216.ref063">
<label>63</label>
<mixed-citation publication-type="journal" xlink:type="simple">
<name name-style="western"><surname>Brown</surname> <given-names>NR</given-names></name>, <name name-style="western"><surname>Noble</surname> <given-names>ME</given-names></name>, <name name-style="western"><surname>Endicott</surname> <given-names>JA</given-names></name>, <name name-style="western"><surname>Johnson</surname> <given-names>LN</given-names></name>. <article-title>The structural basis for specificity of substrate and recruitment peptides for cyclin-dependent kinases</article-title>. <source>Nat Cell Biol</source>. <year>1999</year>;<volume>1</volume>(<issue>7</issue>):<fpage>438</fpage>–<lpage>443</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/15674" xlink:type="simple">10.1038/15674</ext-link></comment> <object-id pub-id-type="pmid">10559988</object-id></mixed-citation>
</ref>
<ref id="pcbi.1005216.ref064">
<label>64</label>
<mixed-citation publication-type="journal" xlink:type="simple">
<name name-style="western"><surname>Zhang</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Yang</surname> <given-names>PL</given-names></name>, <name name-style="western"><surname>Gray</surname> <given-names>NS</given-names></name>. <article-title>Targeting cancer with small molecule kinase inhibitors</article-title>. <source>Nature Rev Cancer</source>. <year>2009</year>;<volume>9</volume>(<issue>1</issue>):<fpage>28</fpage>–<lpage>39</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/nrc2559" xlink:type="simple">10.1038/nrc2559</ext-link></comment> <object-id pub-id-type="pmid">19104514</object-id></mixed-citation>
</ref>
<ref id="pcbi.1005216.ref065">
<label>65</label>
<mixed-citation publication-type="journal" xlink:type="simple">
<name name-style="western"><surname>Bullock</surname> <given-names>AN</given-names></name>, <name name-style="western"><surname>Debreczeni</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Amos</surname> <given-names>AL</given-names></name>, <name name-style="western"><surname>Knapp</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Turk</surname> <given-names>BE</given-names></name>. <article-title>Structure and substrate specificity of the Pim-1 kinase</article-title>. <source>J Biol Chem</source>. <year>2005</year>;<volume>280</volume>(<issue>50</issue>):<fpage>41675</fpage>–<lpage>41682</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1074/jbc.M510711200" xlink:type="simple">10.1074/jbc.M510711200</ext-link></comment> <object-id pub-id-type="pmid">16227208</object-id></mixed-citation>
</ref>
<ref id="pcbi.1005216.ref066">
<label>66</label>
<mixed-citation publication-type="journal" xlink:type="simple">
<name name-style="western"><surname>Feinerman</surname> <given-names>O</given-names></name>, <name name-style="western"><surname>Veiga</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Dorfman</surname> <given-names>JR</given-names></name>, <name name-style="western"><surname>Germain</surname> <given-names>RN</given-names></name>, <name name-style="western"><surname>Altan-Bonnet</surname> <given-names>G</given-names></name>. <article-title>Variability and robustness in T cell activation from regulated heterogeneity in protein levels</article-title>. <source>Science</source>. <year>2008</year>;<volume>321</volume>(<issue>5892</issue>):<fpage>1081</fpage>–<lpage>1084</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1126/science.1158013" xlink:type="simple">10.1126/science.1158013</ext-link></comment> <object-id pub-id-type="pmid">18719282</object-id></mixed-citation>
</ref>
<ref id="pcbi.1005216.ref067">
<label>67</label>
<mixed-citation publication-type="journal" xlink:type="simple">
<name name-style="western"><surname>Hanahan</surname> <given-names>D</given-names></name>, <name name-style="western"><surname>Weinberg</surname> <given-names>RA</given-names></name>. <article-title>Hallmarks of cancer: the next generation</article-title>. <source>Cell</source>. <year>2011</year>;<volume>144</volume>(<issue>5</issue>):<fpage>646</fpage>–<lpage>674</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.cell.2011.02.013" xlink:type="simple">10.1016/j.cell.2011.02.013</ext-link></comment> <object-id pub-id-type="pmid">21376230</object-id></mixed-citation>
</ref>
<ref id="pcbi.1005216.ref068">
<label>68</label>
<mixed-citation publication-type="journal" xlink:type="simple">
<name name-style="western"><surname>Gerlinger</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Rowan</surname> <given-names>AJ</given-names></name>, <name name-style="western"><surname>Horswell</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Larkin</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Endesfelder</surname> <given-names>D</given-names></name>, <name name-style="western"><surname>Gronroos</surname> <given-names>E</given-names></name>, <etal>et al</etal>. <article-title>Intratumor heterogeneity and branched evolution revealed by multiregion sequencing</article-title>. <source>N Engl J Med</source>. <year>2012</year>;<volume>366</volume>(<issue>10</issue>):<fpage>883</fpage>–<lpage>892</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1056/NEJMoa1113205" xlink:type="simple">10.1056/NEJMoa1113205</ext-link></comment> <object-id pub-id-type="pmid">22397650</object-id></mixed-citation>
</ref>
<ref id="pcbi.1005216.ref069">
<label>69</label>
<mixed-citation publication-type="journal" xlink:type="simple">
<name name-style="western"><surname>Little</surname> <given-names>AS</given-names></name>, <name name-style="western"><surname>Balmanno</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Sale</surname> <given-names>MJ</given-names></name>, <name name-style="western"><surname>Newman</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Dry</surname> <given-names>JR</given-names></name>, <name name-style="western"><surname>Hampson</surname> <given-names>M</given-names></name>, <etal>et al</etal>. <article-title>Amplification of the driving oncogene, KRAS or BRAF, underpins acquired resistance to MEK1/2 inhibitors in colorectal cancer cells</article-title>. <source>Sci Signal</source>. <year>2011</year>;<volume>4</volume>(<issue>166</issue>):<fpage>ra17</fpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1126/scisignal.2001752" xlink:type="simple">10.1126/scisignal.2001752</ext-link></comment> <object-id pub-id-type="pmid">21447798</object-id></mixed-citation>
</ref>
<ref id="pcbi.1005216.ref070">
<label>70</label>
<mixed-citation publication-type="journal" xlink:type="simple">
<name name-style="western"><surname>Meads</surname> <given-names>MB</given-names></name>, <name name-style="western"><surname>Gatenby</surname> <given-names>RA</given-names></name>, <name name-style="western"><surname>Dalton</surname> <given-names>WS</given-names></name>. <article-title>Environment-mediated drug resistance: a major contributor to minimal residual disease</article-title>. <source>Nat Rev Cancer</source>. <year>2009</year>;<volume>9</volume>(<issue>9</issue>):<fpage>665</fpage>–<lpage>674</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/nrc2714" xlink:type="simple">10.1038/nrc2714</ext-link></comment> <object-id pub-id-type="pmid">19693095</object-id></mixed-citation>
</ref>
<ref id="pcbi.1005216.ref071">
<label>71</label>
<mixed-citation publication-type="journal" xlink:type="simple">
<name name-style="western"><surname>Gerondakis</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Grossmann</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Nakamura</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Pohl</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Grumont</surname> <given-names>R</given-names></name>. <article-title>Genetic approaches in mice to understand Rel/NF-<italic>κ</italic>B and I<italic>κ</italic>B function: transgenics and knockouts</article-title>. <source>Oncogene</source>. <year>1999</year>;<volume>18</volume>:<fpage>6888</fpage>–<lpage>6895</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/sj.onc.1203236" xlink:type="simple">10.1038/sj.onc.1203236</ext-link></comment> <object-id pub-id-type="pmid">10602464</object-id></mixed-citation>
</ref>
<ref id="pcbi.1005216.ref072">
<label>72</label>
<mixed-citation publication-type="journal" xlink:type="simple">
<name name-style="western"><surname>Kearns</surname> <given-names>JD</given-names></name>, <name name-style="western"><surname>Basak</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Werner</surname> <given-names>SL</given-names></name>, <name name-style="western"><surname>Huang</surname> <given-names>CS</given-names></name>, <name name-style="western"><surname>Hoffmann</surname> <given-names>A</given-names></name>. <article-title>I<italic>κ</italic>B<italic>ϵ</italic> provides negative feedback to control NF-<italic>κ</italic>B oscillations, signaling dynamics, and inflammatory gene expression</article-title>. <source>J Cell Biol</source>. <year>2006</year>;<volume>173</volume>(<issue>5</issue>):<fpage>659</fpage>–<lpage>664</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1083/jcb.200510155" xlink:type="simple">10.1083/jcb.200510155</ext-link></comment> <object-id pub-id-type="pmid">16735576</object-id></mixed-citation>
</ref>
<ref id="pcbi.1005216.ref073">
<label>73</label>
<mixed-citation publication-type="journal" xlink:type="simple">
<name name-style="western"><surname>Mothes</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Busse</surname> <given-names>D</given-names></name>, <name name-style="western"><surname>Kofahl</surname> <given-names>B</given-names></name>, <name name-style="western"><surname>Wolf</surname> <given-names>J</given-names></name>. <article-title>Sources of dynamic variability in NF-<italic>κ</italic>B signal transduction: a mechanistic model</article-title>. <source>BioEssays</source>. <year>2015</year>;<volume>37</volume>(<issue>4</issue>):<fpage>452</fpage>–<lpage>462</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1002/bies.201400113" xlink:type="simple">10.1002/bies.201400113</ext-link></comment> <object-id pub-id-type="pmid">25640005</object-id></mixed-citation>
</ref>
<ref id="pcbi.1005216.ref074">
<label>74</label>
<mixed-citation publication-type="journal" xlink:type="simple">
<name name-style="western"><surname>O’Dea</surname> <given-names>EL</given-names></name>, <name name-style="western"><surname>Barken</surname> <given-names>D</given-names></name>, <name name-style="western"><surname>Peralta</surname> <given-names>RQ</given-names></name>, <name name-style="western"><surname>Tran</surname> <given-names>KT</given-names></name>, <name name-style="western"><surname>Werner</surname> <given-names>SL</given-names></name>, <name name-style="western"><surname>Kearns</surname> <given-names>JD</given-names></name>, <etal>et al</etal>. <article-title>A homeostatic model of I<italic>κ</italic>B metabolism to control constitutive NF-<italic>κ</italic>B activity</article-title>. <source>Mol Syst Biol</source>. <year>2007</year>;<volume>3</volume>:<fpage>111</fpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/msb4100148" xlink:type="simple">10.1038/msb4100148</ext-link></comment> <object-id pub-id-type="pmid">17486138</object-id></mixed-citation>
</ref>
<ref id="pcbi.1005216.ref075">
<label>75</label>
<mixed-citation publication-type="journal" xlink:type="simple">
<name name-style="western"><surname>Millard</surname> <given-names>BL</given-names></name>, <name name-style="western"><surname>Niepel</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Menden</surname> <given-names>MP</given-names></name>, <name name-style="western"><surname>Muhlich</surname> <given-names>JL</given-names></name>, <name name-style="western"><surname>Sorger</surname> <given-names>PK</given-names></name>. <article-title>Adaptive informatics for multifactorial and high-content biological data</article-title>. <source>Nat Methods</source>. <year>2011</year>;<volume>8</volume>(<issue>6</issue>):<fpage>487</fpage>–<lpage>492</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/nmeth.1600" xlink:type="simple">10.1038/nmeth.1600</ext-link></comment> <object-id pub-id-type="pmid">21516115</object-id></mixed-citation>
</ref>
<ref id="pcbi.1005216.ref076">
<label>76</label>
<mixed-citation publication-type="journal" xlink:type="simple">
<name name-style="western"><surname>Aoki</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Yamada</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Kunida</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Yasuda</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Matsuda</surname> <given-names>M</given-names></name>. <article-title>Processive phosphorylation of ERK MAP kinase in mammalian cells</article-title>. <source>Proc Nat Acad Sci USA</source>. <year>2011</year>;<volume>108</volume>:<fpage>12675</fpage>–<lpage>12680</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1073/pnas.1104030108" xlink:type="simple">10.1073/pnas.1104030108</ext-link></comment> <object-id pub-id-type="pmid">21768338</object-id></mixed-citation>
</ref>
<ref id="pcbi.1005216.ref077">
<label>77</label>
<mixed-citation publication-type="journal" xlink:type="simple">
<name name-style="western"><surname>Aoki</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Takahashi</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Kaizu</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Matsuda</surname> <given-names>M</given-names></name>. <article-title>A quantitative model of ERK MAP kinase phosphorylation in crowded media</article-title>. <source>Sci Rep</source>. <year>2013</year>;<volume>3</volume>:<fpage>1541</fpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/srep01541" xlink:type="simple">10.1038/srep01541</ext-link></comment> <object-id pub-id-type="pmid">23528948</object-id></mixed-citation>
</ref>
<ref id="pcbi.1005216.ref078">
<label>78</label>
<mixed-citation publication-type="journal" xlink:type="simple">
<name name-style="western"><surname>Sun</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Yi</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Yang</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>Wei</surname> <given-names>W</given-names></name>, <name name-style="western"><surname>Ding</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Jia</surname> <given-names>Y</given-names></name>. <article-title>Enhancement of tunability of MAPK cascade due to coexistence of processive and distributive phosphorylation mechanisms</article-title>. <source>Biophys J</source>. <year>2014</year>;<volume>106</volume>(<issue>5</issue>):<fpage>1215</fpage>–<lpage>1226</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.bpj.2014.01.036" xlink:type="simple">10.1016/j.bpj.2014.01.036</ext-link></comment> <object-id pub-id-type="pmid">24606945</object-id></mixed-citation>
</ref>
<ref id="pcbi.1005216.ref079">
<label>79</label>
<mixed-citation publication-type="journal" xlink:type="simple">
<name name-style="western"><surname>Zhang</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Spevak</surname> <given-names>W</given-names></name>, <name name-style="western"><surname>Zhang</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Burton</surname> <given-names>EA</given-names></name>, <name name-style="western"><surname>Ma</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Habets</surname> <given-names>G</given-names></name>, <etal>et al</etal>. <article-title>RAF inhibitors that evade paradoxical MAPK pathway activation</article-title>. <source>Nature</source>. <year>2015</year>;<volume>526</volume>(<issue>7574</issue>):<fpage>583</fpage>–<lpage>586</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/nature14982" xlink:type="simple">10.1038/nature14982</ext-link></comment> <object-id pub-id-type="pmid">26466569</object-id></mixed-citation>
</ref>
</ref-list>
</back>
</article>